Back to GetFilings.com
1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
---------------
FORM 10-K
FOR ANNUAL AND TRANSITION REPORTS PURSUANT TO SECTIONS 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
(MARK ONE)
[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
For the fiscal year ended December 31, 1997
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from to
Commission file number: 0-28440
CARDIOVASCULAR DYNAMICS, INC.
(Exact name of Registrant as specified in its charter)
Delaware 68-0328265
(State of Incorporation) (I.R.S. Employer Identification No.)
13700 Alton Parkway, Suite 160, Irvine, California 92618
(Address of principal executive offices, including zip code)
Registrant's telephone number, including area code: (714) 457-9546
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Name of each exchange on which registered
- ------------------- -----------------------------------------
None None
Securities to be registered pursuant to Section 12(g) of the Act: Common Stock,
$.001 par value.
Indicate by check mark whether the registrant: (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
Registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes [X] No [ ]
Indicate by a check mark if disclosure of delinquent filers pursuant to
Item 405 of Regulation S-K is not contained herein, and will not be contained,
to the best of registrant's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-K or any
amendment to this Form 10-K. [ ]
The aggregate market value of the voting stock held by non-affiliates of
the Registrant, as of March 1, 1998, was approximately $ 30,992,000 (based upon
the closing price for shares of the Registrant's Common Stock as reported by the
Nasdaq National Market for the last trading date prior to that date). Shares of
Common Stock held by each officer, director and holder of 5% or more of the
outstanding Common Stock have been excluded in that such persons may be deemed
to be affiliates. This determination of affiliate status is not necessarily a
conclusive determination for other purposes.
On March 1, 1998, approximately 9,413,000 shares of the Registrant's
Common Stock, $.001 par value, were outstanding.
DOCUMENTS INCORPORATED BY REFERENCE.
Portions of the Registrant's Proxy Statement for the 1998 Annual Meeting of
Stockholders to be held on May 19, 1998 are incorporated by reference into Part
III.
2
PART I
ITEM 1. BUSINESS
CardioVascular Dynamics, Inc. ("CVD" or the "Company") designs, develops,
manufactures and markets catheters used to treat certain vascular diseases. The
Company's catheters are used in conjunction with angioplasty and other
interventional procedures such as vascular stenting and drug delivery. The
Company's proprietary Focus and Multiple Microporous Membrane ("M3")
technologies enable physicians to deliver therapeutic radial force, stents,
drugs or contrast media accurately and effectively to the treatment site, and
also allow the perfusion of blood during an interventional procedure. The
Company believes that the combination of these technologies on a
multiple-purpose catheter enables physicians to effectively perform challenging
interventional procedures, resulting in improved treatment outcomes and lower
costs. The Company owns the rights to 23 issued U.S. patents covering certain
aspects of its catheter technologies.
CVD has utilized its core proprietary technologies to develop catheters
that provide clinical and cost benefits in the treatment of vascular diseases.
The Company's catheters are designed to address three principal challenges
facing cardiologists: restenosis of a treated vessel, chronic total occlusions
and acute reclosure of a vessel during or soon after a procedure. The Company's
patented Focus technology combines compliant and non-compliant balloon materials
on a single catheter, creating an angioplasty balloon that has an adjustable,
larger center diameter with fixed, smaller diameters at each end. These
characteristics allow a single balloon to expand to multiple diameters, enabling
the physician to perform interventional procedures in vessels of varying
diameters and anatomical locations. The Company's proprietary M3 technology
combines multiple membranes of polymeric balloon material to form a single
balloon that enables the accurate delivery of drugs or contrast agents to the
lesion or thrombus site. The M3 technology can also be utilized to provide
perfusion of blood during an interventional procedure. The Company believes that
the Focus and M3 technologies may enable physicians to cost-effectively treat
vascular diseases by reducing the cost of those procedures which require more
than one catheter.
FORWARD-LOOKING STATEMENTS
Certain statements contained in this Annual Report on Form 10-K,
including, without limitation, statements containing the words "believes,"
"anticipates," "estimates," "expects" and words of similar import, constitute
"forward-looking statements" within the meaning of Private Securities Litigation
Reform Act of 1995. Such forward-looking statements involve known and unknown
risks, uncertainties and other factors that may cause the actual results,
performance or achievements of the Company, or industry results, to be
materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Given these
uncertainties, prospective investors are cautioned not to place undue reliance
on such forward-looking statements. The Company disclaims any obligation to
update any such factors or to publicly announce the result of any revisions to
any of the forward-looking statements contained or incorporated by reference
herein to reflect any events or developments.
PRODUCTS
Catheter Products
The Company has utilized its Focus and M3 technologies to develop catheter
products that address the challenges physicians experience in treating vascular
diseases. These technologies are available in various combinations on a
multiple-purpose catheter, thereby enabling physicians to cost-effectively treat
vascular disease. The Company's products are designed to be low profile (small,
uninflated diameter), enabling cardiologists to advance them along narrow
vessels, and flexible and trackable, enabling cardiologists to advance and
control them accurately within the vasculature.
1.
3
The following table lists CVD's currently marketed products:
FIRST
COMMERCIAL
PRODUCTS INTENDED APPLICATIONS U.S. REGULATORY STATUS SALE
- -------- --------------------- ---------------------- ----------
Focus Catheters PTCA (i.e., balloon
ARC angioplasty in coronary
Over-the-wire design...... arteries) PMA Supplement Approved Q3 1996
FACT/FACT 15
Over-the-wire design...... PTCA or Stent Delivery(2) Approved Q1 1996
Lynx F/X
Rail Design............... PTCA or Stent Delivery(2) N/A(1) Q1 1997
M3 Catheters
Bullett Hi-Flo Total Occlusion Drug
Over-the-wire design...... Delivery (coronary) 510(k) Clearance Q2 1996
Bullett F/X Total Occlusion Drug
Rail design............... Delivery (coronary) 510(k) Clearance Q2 1996
Periflow Small Vessel
Over-the-wire design...... PTA/Drug Delivery 510(k) Clearance Q1 1996
(1) Available only outside the United States due to patent restrictions.
(2) Not approved in the United States for stent delivery. The marketing of
this product in the United States for such use will require the Company to
obtain a PMA supplement approval. The Company is not currently seeking
such approval.
Focus Catheters. The Company's Focus products have a catheter balloon that
has an adjustable, larger center diameter and smaller, fixed, distal and
proximal diameters. This characteristic provides increased utility in a variety
of therapeutic treatments and anatomical locations. Existing uniform diameter
catheters require cardiologists to use multiple balloons to treat vessels of
varying diameters, resulting in unnecessary costs. In addition, the Focus
catheters may deliver stents more effectively by focusing the radial deployment
force on the stented section, rather than along the entire balloon, which may
reduce the damage to the adjacent vessel.
M3 Catheters. The Company's M3 catheters offer cardiologists the ability
to deliver drugs or contrast media to the treatment site accurately, and enable
the perfusion of blood during angioplasty procedures. These capabilities may be
combined on an interventional catheter to provide cardiologists the
functionality of multiple catheters, in a single, cost-effective device. The
accurate delivery of drugs to the treatment site may enhance the effectiveness
of these pharmacological agents and may reduce the quantity of drug required to
achieve an acceptable outcome. Drugs are utilized by cardiologists to reduce the
occurrence of restenosis and acute reclosure, and to dissolve blood clots.
Typically, therapeutic drug delivery is accomplished by means of an intravenous
injection, a method that requires larger amounts of drug than is clinically
required because the drug is diffused throughout the body. The Company's M3
technology enables cardiologists to deliver drugs directly to the treatment site
through a catheter's lumen, or interior channel. While CVD's M3 site-specific
drug delivery catheters are currently marketed internationally, they can only be
used in the United States to administer drugs specifically approved by the FDA
for administration by such catheters. The multiple lumens of the catheter may
also be used to deliver contrast media for angiographic viewing when advancing
the catheter along a totally occluded vessel. Traditional catheters must be
removed to inject contrast media into a total occlusion. Finally, the M3
technology can be utilized to provide perfusion of blood during an
interventional procedure. This perfusion capability allows the balloon to be
inflated for longer durations and reduces the number of inflations and
deflations required in certain procedures, and may increase the clinical
effectiveness of the treatment.
Stent Products
The Company's line of coronary stents provide the physician with unique
products which have varying measures of strength and flexibility to allow
optimal placement and stenting characteristics to aid in the minimization of
restenosis.
2.
4
FIRST
PRODUCTS INTENDED APPLICATIONS U.S. REGULATORY STATUS COMMERCIAL SALE
- -------- --------------------- ---------------------- ---------------
DART Stent Coronary Stenting N/A (1) Q1 1997
Enforcer Stent Coronary Stenting N/A (1) Q1 1997
Synthesis Stent Coronary Stenting N/A (1) Q1 1998
Chunnel Stent Peripheral Vascular Stenting N/A (1) Q4 1997
(1) Available only outside the United States due to patent restrictions.
Vascular Access Products
The Company's vascular access products utilize patented technology to
provide rapid, accurate access to the body's vascular system for guidewire and
catheter entry. The principal product, called the SmartNeedle, was acquired from
Advanced Cardiovascular Systems, Inc., a subsidiary of Guidant Corporation
("ACS") and is based on Doppler ultrasound technology. A miniaturized ultrasound
chip is placed at the tip of a disposable ultrasonic probe which is then placed
inside a conventional vascular access needle. The probe is then connected to a
separate reusable monitor. Once placed in the body as a part of the access
needle, the Doppler chip emits an audible signal which enables the physician to
more accurately determine whether or not the needle resides in the proper
location within the intended arterial or venous lumen. Once positioned properly,
the probe is removed, leaving the conventional access needle in place within the
artery or vein. Since introduction, the SmartNeedle's primary use has been in
interventional cardiology and radiology procedures. A line of products featuring
much smaller needle sizes was introduced as P.D. Access devices. These
needles contain probes with more advanced Doppler ultrasound chip design and
manufactruing technolgy.
NEW PRODUCT DEVELOPMENT
The Company focuses its research and development efforts on utilizing the
Company's proprietary processes and patented technologies to develop
cost-effective products that address existing and emerging clinical demands. The
Company's strategy is to refine its existing technologies and to enhance the
performance of its existing product offerings, including efforts to make its
Focus and M3 products lower profile, more flexible and trackable, and operable
at a broader range of inflation pressures. The Company is developing additional
products utilizing combinations of its technologies that may provide
cardiologists greater therapeutic applicability in a single device. The Company
is also in the process of developing unique catheter designs intended to provide
enhanced delivery of therapeutic radial force and pharmacological agents. The
Company will be required to seek FDA approval for any new product and it is
expected that some of these products will be subject to the PMA process. The
Company's current new product development efforts are summarized in the table
below.
PRODUCTS INTENDED APPLICATIONS U.S. REGULATORY STATUS
- -------- --------------------- ----------------------
Focus Catheters
Guardian
Over-the-wire design.......... PTCA or Stent Delivery PMA Supplement Filed
M3 Catheters
Transport(1)................... PTCA/Drug Delivery Development Stage
Periflow Large-Vessel.......... PTA/Drug Delivery 510(k) Clearance
MicroMembrane Radiation(2) Delivery of Radioactive Materials for Development Stage
Restenosis Prevention
Vascular Stent
SEMS Stent..................... Peripheral Vascular Stenting Development Stage
Coronary Stents
SEMS Stent..................... Coronary Stenting Development Stage
Synthesis Stent................ Coronary Stenting N/A (3)
Enforcer Stent................. Coronary Stenting N/A (3)
PD Access...................... Vascular Access 510(k) Clearance
3.
5
- ----------
(1) Licensed to SCIMED. See "--Strategic Relationships."
(2) Licensed to Radiance Medical Systems, Inc. See "--Strategic
Relationships."
(3) Available only outside the United States due to patent restrictions.
TECHNOLOGY
The Company has developed proprietary material manufacturing processes
that it has utilized to develop patented interventional catheters. Traditional
balloon extrusion technology does not enable the combination of compliant and
non-compliant materials, resulting in a catheter that can be inflated only to a
uniform diameter. The Company's Focus technology bonds a membrane between
compliant and non-compliant materials, resulting in a balloon with a large
center diameter and smaller, fixed diameters at each end. The center compliant
section of the Focus catheter enlarges predictably at a rate of 0.1mm per
atmosphere of pressure when inflation pressures exceed six atmospheres. The ends
of the balloon remain at their nominal diameters and do not expand with
increased pressure. The Focus capability enables cardiologists to deliver stents
or therapeutic radial force accurately to the treatment site, while minimizing
the force applied to adjacent tissue. Conventional uniform diameter catheters
may damage healthy vessel sections, as these sections receive as much radial
force as do the diseased sites. It is widely believed that vessel wall damage
may lead to acute reclosure of the vessel or restenosis.
The Company's M3 technology creates a membrane by applying mechanical and
radiation treatment to standard polymeric balloon material during the extrusion
process. Microporous holes are then drilled in the resulting material by
proprietary mechanical or laser drilling processes. CVD's M3 technology also
enables blood to flow through a coil lumen or inner shaft of the catheter,
allowing perfusion to the distal vessels (those beyond the treatment site)
during angioplasty or drug delivery. Prior to inflation, the balloon acts as a
shaft for the distal portion of the catheter. Once the balloon is inflated, the
cardiologist advances a coil into and through the inner lumen of the inflated
balloon. The coil supports the balloon during balloon angioplasty or drug
delivery and facilitates the perfusion of the distal vessels. The M3 technology
enables the Company to combine balloon angioplasty and perfusion capabilities on
a single catheter in a profile comparable to standard balloon angioplasty
catheters without perfusion capability. The Company believes that the M3
technology also enables it to combine PTCA and perfusion capabilities on a
single catheter with a lower profile than any currently marketed catheter with
similar capabilities.
The Company's Intraluminal Devices, Inc. ("IDI") subsidiary, which was
acquired in October 1996, utilizes patented technology in the development of
medical stents for the treatment of patients with vascular disease caused by
aneurysms or atherosclerosis. IDI is developing a compact, self-expanding
metallic stent with a micro-porous surface for use as either a stent or a stent
graft. By selecting metal foil of the proper thickness and tensile strength, and
heat-treating it in the proper shape, the Company believes it will be able to
form devices with low profiles, high expansion ratios and excellent hoop
strength, which are factors critical for successful device placement. Two
patents have been issued to date for IDI related technology. In March 1998, the
Company completed animal feasibility studies and plans to begin clinical trials
for CE Mark approval in April 1998 and under an IDE before the end of 1998 for
the MP Stent. The MP Stent is designed for use in peripheral vascular stenting.
There can be no assurance that IDI will successfully complete the development of
any products or that any such products will receive any required regulatory
approvals.
MANUFACTURING
With the exception of certain final assembly and sterilization procedures
for those products designed to be sold only outside the United States, and the
manufacture of those products which the Company has licensed to third parties,
all of the Company's products are produced in its facilities in Irvine,
California. The Company fabricates certain proprietary components, then
assembles, inspects, tests and packages all components into finished products.
By designing and assembling its catheter products, the Company believes it is
better able to control quality and costs, limit third-party access to its
proprietary technology, and manage manufacturing process enhancements and new
product introductions. In addition, the Company purchases many standard and
custom-built components from independent suppliers and subcontracts certain
processes from independent vendors. Most of these components
4.
6
and processes are available from more than one vendor. However, certain
manufacturing processes are currently performed by single vendors. While the
Company believes that there are other vendors available to perform these
processes, an interruption of performance by any of these vendors could have a
material adverse effect on the Company's ability to manufacture its products
until a new source of supply were qualified and, as a result, could have an
adverse effect on the Company's business, financial condition and results of
operations.
The Company has obtained the right to affix CE (Conformite Europeene)
marking to all of its products sold in all countries of the European Economic
Area and Switzerland, except the Synthesis coronary stent line of products. CE
marking is a European symbol of conformance to strict product manufacturing and
quality system standards. As part of the CE marking process, the Company also
received ISO 9001/EN46001 certification with respect to the manufacturing of all
of its currently marketed products.
The Company's success will depend in part upon its ability to manufacture
its products in compliance with ISO 9001, the FDA's quality system regulations
("QSR") requirements, California Department of Health Services ("CDHS")
licensing and other regulatory requirements, in sufficient quantities and on a
timely basis, while maintaining product quality and acceptable manufacturing
costs. The Company began manufacturing certain of its products at its facilities
in July 1995. The Company also introduced a significant number of new products
in 1996 and 1997. Accordingly, the Company has limited experience in
manufacturing its products. The Company has undergone and expects to continue to
undergo regular QSR inspections in connection with the manufacture of its
products at the Company's facilities. The Company's success will depend, among
other things, upon its ability to efficiently manage the simultaneous
manufacture of different products and to integrate the manufacture of new
products with existing products. There can be no assurance that the Company will
not encounter difficulties in scaling up production of new products, including
problems involving production yields, quality control and assurance, component
supply and shortages of qualified personnel. The Company's failure to
successfully commence the manufacturing of these new products, or to increase
production volumes of new and existing products in a timely manner, would
materially adversely affect the Company's business, financial condition and
results of operations. Failure to increase production volumes in a timely or
cost-effective manner or to maintain compliance with ISO 9001, QSR requirements,
CDHS or other regulatory requirements could have a material adverse effect on
the Company's business, financial condition and results of operations. See "Item
7. Management's Discussion and Analysis of Financial Condition and Results of
Operations--Risk Factors--Limited Manufacturing Experience."
MARKETING AND SALES
The Company's products are sold in the United States and international
markets, principally Europe and Japan. However, certain of the Company's
products are not available in each market due to regulatory and intellectual
property restrictions. The Company currently sells its products through a
combination of strategic partners, medical device distributors and eleven direct
sales personnel. CVD also has distribution agreements with 30 companies covering
35 countries outside the United States and Japan. CVD distributed certain
products in Japan through an exclusive distribution agreement with Fukuda, which
the Company terminated in April 1997. The Company entered into an exclusive
distribution agreement in Japan in May 1997 with Cathex which expires in
January 2001. Sales of the Company's products to Fukuda accounted for 18%, 15%
and 7% of the Company's total product sales in 1995, 1996 and 1997,
respectively. Sales to Cathex in 1997 accounted for 13% of the Company's total
product sales. In addition, sales to Johnson & Johnson Interventional Systems
("JJIS") accounted for 12% of total product sales in 1995. And, sales to
Medtronic accounted for 22% and 13% of total product sales in 1996 and 1997,
respectively. The Company intends to expand its sales and marketing capability
and to distribute selected new products through strategic partnerships. See
"Item 7. Management's Discussion and Analysis of Financial Condition and Results
of Operations--Risk Factors--Limited Marketing and Sales Resources; Dependence
Upon Strategic Relationships."
In 1995, 1996 and 1997, total export sales were $2,054,000, $3,514,000 and
$6,579,000, respectively, or approximately 59%, 42% and 58% respectively, of
total product sales. In 1995, 1996 and 1997 sales to Europe accounted for
$1,179,000, $1,614,000 and $3,020,000, respectively; sales to Japan represented
$744,000, $1,240,000 and $2,350,000, respectively; and sales to Latin America
represented $131,000, $243,000 and $253,000, respectively. The Company expects
to continue to derive significant revenue from international sales and therefore
a significant portion of the Company's revenues will continue to be subject to
the risks associated with international sales, including economic or political
instability, shipping delays, changes in applicable regulatory policies,
5.
7
inadequate protection of intellectual property, fluctuations in foreign currency
exchange rates and various trade restrictions, all of which could have a
significant impact on the Company's ability to deliver products on a competitive
and timely basis. However, all of the Company's foreign sales are denominated in
dollars, except for sales in Germany by CVD Germany, which were immaterial to
the Company's business in 1997. Future imposition of, or significant increases
in the level of, customs duties, export quotas or other trade restrictions,
could have an adverse effect on the Company's business, financial condition and
results of operation. In foreign countries, the Company's products are subject
to a wide variety of governmental review and certification. The regulation of
medical devices, particularly in the European Community, continues to expand and
there can be no assurance that new laws or regulations will not have an adverse
effect on the Company. See Note 1 of Notes to Consolidated Financial Statements.
See "Item 7. Management's Discussion and Analysis of Financial Condition and
Results of Operations--Risk Factors--Dependence Upon International Sales."
In July 1997, the Company acquired all of the Common Stock of Clinitec
GmbH ("Clinitec") its independent distributor in Germany and Switzerland, in
exchange for the assumption of the assets and liabilities of Clinitec. See Note
2 of Notes to Consolidated Financial Statements.
POST-MARKETING CLINICAL STUDIES
The Company has completed the clinical trials required for FDA approval of
those products which are marketed in the United States. In addition to those
trials, the Company is also sponsoring a controlled, randomized, multicenter
clinical study in the United States to continue to evaluate the clinical and
economic value of its core technologies. Data from this study is being
accumulated and analyzed to support the marketing of the Company's current
products.
In a Comparative Performance and Pathological Study conducted by the
Division of Cardiology at the University of Texas Department of Medicine, the
Company's FACT catheter was compared with conventional PTCA catheters from other
leading manufacturers in an animal study. The investigators concluded that the
use of the FACT catheter resulted in reduced arterial damage without reduction
in catheter performance as determined by catheter preparation, trackability,
pushability, inflation/deflation and angiographic visualization.
A second study compared the Focus PTCA catheter with conventional PTCA
catheters. The Focus Lesion Expansion Optimizes Results Study ("FLEXOR Study")
evaluated the efficacy of Focus technology in improving clinical results
following angioplasty procedures. Success was evaluated based on the ability of
Focus technology to improve the minimal lumen diameter ("MLD") of the arterial
opening, to increase safety and to reduce the number of catheters necessary for
PTCA procedures. MLD is a commonly-used measurement of the ability of a
therapeutic tool to open a blocked artery and reestablish required blood flow.
The FLEXOR Study was commenced in the fourth quarter of 1996 and was completed
in the first quarter of 1997. Results of the study were presented at the 1997
TCT meeting in Washington D.C. Data from this pilot study of 80 patients
demonstrated a trend toward lower balloon usage with Focus technology,
especially when stent implantation was required, without any increase in
complications. Additionally, the Focus technology group of patients had a lower
residual stenosis than the conventional angioplasty group.
Certain of the Company's products which utilize Focus technology have
received FDA approval for PTCA and PTA indications. However, none of these
products has received FDA approval for use in stent delivery. An
investigator-controlled study is currently testing the Company's Focus
technology with respect to stent implantation. The Optimal Stent Implantation
Study ("OSTI-2 Study") is evaluating the ability of stent delivery with Focus
technology compared with conventional delivery techniques to reduce acute
outcomes and restenosis rates. The study is being conducted using two patient
subgroups of approximately 100 patients each divided according to vessel size.
In the first group, stent delivery is being evaluated in vessels greater than
three millimeters in diameter; in the second group stent delivery is being
evaluated in vessels less than three millimeters in diameter. Each subgroup
presents different clinical issues related to stent delivery and the OSTI-2
Study protocol is evaluating the efficacy of Focus technology in each subgroup.
The OSTI-2 Study began in February 1996 and completed enrollment of patients in
the first quarter of 1998. A six month follow-up is in progress. Preliminary
results of the study were reported at the American Heart Association 20th
Scientific Sessions in November 1997 and additional results will be reported at
the American College of Cardiology meeting in March 1998. Early results
demonstrate that Focus technology facilitates achieving a larger in stent MLD
following conventional stent expansion techniques and also following optimal
PTCA. These increased MLDs were achieved without increased complication rates.
The Company also intends to sponsor additional studies from time to time
to assess the value of, and to expand clinical indications of, its existing and
new technologies. The Company is planning a clinical study to expand the
6.
8
clinical uses of its Focus technology catheters to include balloon dilatation of
previously deployed stents in order to properly implant the stent in the
arterial wall of small coronary vessels. This study will include approximately
100 patients and is expected to be completed in 1998.
STRATEGIC RELATIONSHIPS
The Company evaluates on an ongoing basis potential strategic
relationships with corporate and other partners where such relationships may
complement and expand CVD's research, development, sales and marketing
capabilities. The Company is currently a party to four such agreements,
described below.
Advanced CardioVascular Systems, Inc. In January 1995, the Company entered
into a license agreement with Advamced CardioVascular Systems, Inc. ("ACS"). The
parties subsequently confirmed their understanding with respect to certain
matters in a second agreement dated March 4, 1996 (collectively, the "ACS
Agreements"). Under the ACS Agreements, the Company acquired certain rights to
ACS' SmartNeedle technology, subject to the payment of certain royalties. ACS
was granted the option to acquire the exclusive worldwide rights to certain CVD
perfusion technology, which ACS exercised on February 14, 1996. As a result, ACS
had an exclusive worldwide right to develop, manufacture and market the
Company's MAC I product line. The agreement included a 30-day termination clause
for ACS, and in February 1998 the partners agreed to terminate the MAC I
agreement.
SCIMED Life Systems, Inc. The Company has entered into a Stock Purchase
and Technology License Agreement, dated September 10, 1994 with SCIMED, now a
unit of Boston Scientific Corporation, (the "SCIMED Agreement"). Pursuant to the
SCIMED Agreement, SCIMED purchased a 19% equity position in the Company. SCIMED
was also granted an exclusive worldwide license to certain combined
site-specific drug delivery and coronary angioplasty technology, including the
Company's Transport products, for use in the cardiovascular field in exchange
for license and royalty fees. The SCIMED Agreement also requires CVD to provide
certain technical assistance and to perform additional research and development
relating to the licensed technology in exchange for fees and reimbursement of
expenses. In the event that CVD's SCIMED-funded research and development efforts
result in improvements to the licensed technology, SCIMED will have an exclusive
worldwide license to the technology in the cardiovascular field and a
non-exclusive license outside the cardiovascular field, both of which are
subject to the payment of royalties. The SCIMED Agreement may be terminated in
the event of breach on 90 days notice by the non-breaching party (or on 30 days
notice in certain limited circumstances) or by SCIMED upon 180 days notice.
Fukuda Denshi Co., Ltd. The Company entered into a Distribution Agreement,
dated May 28, 1993, with Fukuda Denshi Co., Ltd. (the "Fukuda Agreement"),
whereby Fukuda served as CVD's exclusive distributor for certain of the
Company's products in Japan. In exchange for this exclusive distributorship,
Fukuda paid a fee to CVD in addition to payments owing upon the purchase of the
products. Fukuda also agreed to undertake all necessary clinical trials to
obtain approval from Japanese regulatory authorities for the sale of the
products in Japan. Fukuda's purchases under the Fukuda Agreement were subject to
certain minimum requirements. In July 1995 and May 1996, the distribution
agreement with Fukuda was amended to grant Fukuda exclusive distribution rights
to additional CVD products. Under these amendments, the Company received
$750,000 which converted into the right to receive 62,500 shares of Common Stock
upon the consummation of the Company's initial public offering on June 19, 1996.
Fukuda received these shares on November 29, 1996. The Company terminated the
agreement with Fukuda in May 1997, and replaced Fukuda with Cathex Co., Ltd.
Cathex Co., Ltd. The Company entered into a Distribution Agreement, dated
May 1, 1997 with Cathex Co., Ltd. ("Cathex"), whereby Cathex serves as CVD's
exclusive distributor for certain of the Company's products in Japan. In
exchange for this exclusive distributorship, certain Cathex shareholders agreed
to purchase $200,000 of CVD common stock (approximately 25,000 shares) and
Cathex ageed to purchase predetermined minimum quantities of the Company's
products. The initial term of the agreement expires on January 1, 2001 and is
subject to a five-year extension. The agreement may be terminated in the event
of breach upon 90 days notice by the non-breaching party, subject to cure within
the notice period.
Endosonics Corporation. The Company has entered into a license agreement
with Endosonics Corporation ("EndoSonics"), dated December 22, 1995 (the
"EndoSonics Agreement"), pursuant to which CVD granted EndoSonics the
non-exclusive, royalty-free right to CVD's Focus technology for the development
and sale of a
7.
9
combined Focus/Ultrasound product. In exchange, CVD received the non-exclusive,
royalty-free right to submit PMA supplement applications utilizing an EndoSonics
PMA as a reference and to manufacture and distribute CVD products as a
supplement to the EndoSonics PMA. In February 1998, the FDA approved the
Company's PMA application and, as a result, the CVD can obtain independent FDA
supplemental approvals on its products. The EndoSonics Agreement may be
terminated in the event of breach upon 60 days notice by the nonbreaching party,
subject to the breaching party's right to cure. In addition, in March of 1996,
EndoSonics purchased 400,000 shares of CVD's Series B Preferred Stock for a
purchase price of $8,000,000, which converted into 800,000 shares of Common
Stock upon the consummation of the Company's initial public offering on June 19,
1996. In February 1998, the Company repurchased 300,000 shares of its common
stock from Endosonics for an aggregate price of $1,275,000.
Medtronic, Inc. On July 15, 1996, the Company entered into co-distribution
agreements with Medtronic, Inc. ("Medtronic") providing for the co-distribution
of the Company's FACT, CAT and ARC balloon angioplasty catheters. Under the
terms of these agreements, Medtronic purchased a minimum number of angioplasty
catheters manufactured by the Company for distribution worldwide for a period of
up to three years. Specific products to be distributed by Medtronic would differ
in individual country markets. The initial term of the Medtronic agreements was
for a period of three years from the date of first delivery of a product. In May
of 1997, Medtronic advised the Company of its election to not make minimum
purchases of product for the second year of the agreement. In June 1997,
Medtronic informed CVD that it would not fulfill its commitment for the first
year of the agreement and that it did not believe it was required to fulfill
such commitment. This dispute adversely affected the Company's financial results
for the second half of 1997, in that Medtronic did not fulfill its commitment to
purchase an additional $1,300,000 in products. See Note 1 to the Consolidated
Financial Statements.
Radiance Medical Systems, Inc. In August 1997, the Company entered into an
agreement with Radiance Medical Systems, Inc. ("Radiance"), a 31% equity
investee of the Company, to license certain angioplasty technology to be used in
conjunction with its development, manufacturing and commercialization of
products for the delivery of radiation therapy to the body to treat restenosis
resulting from angioplasty. Under the terms of the agreement, Radiance is
obligated to pay the Company royalties based upon the sales of licensed
products, subject to a minimum payment of $10,000 per year for the two years
following March 1998 and an overall minimum royalty of $500,000 from the
inception of the agreement to January 1, 2005, to maintain its exclusive
license. The agreement may be terminated, subject to a cure period, upon sixty
days notice by the non-breaching party.
PATENTS AND PROPRIETARY INFORMATION
The Company's policy is to protect its proprietary position by, among
other methods, filing U.S. and foreign patent applications to protect
technology, inventions and improvements that are important to the development of
its business. The Company has twenty-three issued U.S. patents covering certain
aspects of its catheter technology and licenses, vascular access and SEMS stent
technology. No assurance can be given that any issued patents will provide
competitive advantages for the Company's products, or that they will not be
challenged or circumvented by competitors.
The interventional cardiovascular market in general and the balloon
angioplasty catheter market (including the type of catheters offered by CVD) in
particular have been characterized by substantial litigation regarding patent
and other intellectual property rights. There can be no assurance that the
Company's products do not infringe such patents or rights. During 1997, the
Company was sued for trademark infringement regarding the Company's use of the
product name "Lynx" in connection with one of the Company's balloon angioplasty
catheter product lines. CVD paid no monetary damages but agreed to a consent
judgment which prohibits the Company from using this name in the United States.
In the event that any such third-parties assert claims against the Company for
patent infringement and such patents are upheld as valid and enforceable, the
Company could be prevented from utilizing the subject matter claimed in such
patents, or would be required to obtain licenses from the owners of any such
patents or redesign its products or processes to avoid infringement. There can
be no assurance that such licenses would be available or, if available, would be
so on terms acceptable to the Company or that the Company would be successful in
any attempt to redesign its products or processes to avoid infringement. In
addition, foreign intellectual property laws may not provide protection
commensurate with that provided by U.S. intellectual property laws, and there
can be no assurance that foreign intellectual property laws will adequately
protect the Company's intellectual property rights abroad. The
8.
10
Company also relies on trade secrets and proprietary technology and enters into
confidentiality and non-disclosure agreements with its employees, consultants
and advisors. There can be no assurance that the confidentiality of such trade
secrets or proprietary information will be maintained by employees, consultants,
advisors or others, or that the Company's trade secrets or proprietary
technology will not otherwise become known or be independently developed by
competitors in such a manner that the Company has no practical recourse.
Litigation may be necessary to defend against claims of infringement or
invalidity, to enforce patents issued to the Company or to protect trade
secrets. There can be no assurance that any such litigation would be successful.
Any litigation could result in substantial costs to, and diversion of resources
by, the Company and its officers, which would have a material adverse effect on
its business, financial condition and results of operations. See "Item 7.
Management's Discussion and Analysis of Financial Condition and Results of
Operations--Risk Factors--Reliance on Patents and Proprietary Technology; Risk
of Patent Infringement."
COMPETITION
The Company believes that the primary competitive factors in the market
for interventional cardiology devices are: clinical effectiveness, product
safety, catheter size, flexibility and trackability, ease of use, reliability,
price and availability of third party reimbursement. In addition, a company's
distribution capability and the time in which products can be developed and
receive regulatory approval are important competitive factors. The Company
believes it competes favorably with respect to the foregoing factors. The
Company also believes that its competitive position is dependent upon its
ability to continue to develop innovative new catheter technologies and obtain
rapid regulatory approval.
Competition in the market for devices used in the treatment of
cardiovascular and peripheral vascular disease is intense, and is expected to
increase. The interventional cardiology market is characterized by rapid
technological innovation and change, and the Company's products could be
rendered obsolete as a result of future innovations. The Company's catheters and
other products under development compete or will compete with catheters marketed
by a number of manufacturers, including ACS, SCIMED, JJIS and Cordis
Corporation, subsidiaries of Johnson & Johnson, Medtronic, Inc., C.R. Bard, Inc.
and Schneider USA, a subsidiary of Pfizer, Inc. Such companies have
significantly greater financial, management and other resources, established
market positions, and significantly larger sales and marketing organizations
than does the Company. The Company also faces competition from manufacturers of
other catheter-based atherectomy devices, vascular stents and pharmaceutical
products intended to treat vascular disease. In addition, the Company believes
that many of the purchasers and potential purchasers of the Company's products
prefer to purchase catheter products from a single source. Accordingly, many of
the Company's competitors, because of their size and range of product offerings,
have a competitive advantage over the Company. There can be no assurance that
the Company's competitors will not succeed in developing or marketing
technologies and products that are more clinically effective or cost effective
than any that are being marketed or developed by the Company, or that such
competitors will not succeed in obtaining regulatory approval for introducing or
commercializing any such products prior to the Company. See "Item 7.
Management's Discussion and Analysis of Financial Condition and Results of
Operations--Risk Factors--Significant Competition."
THIRD-PARTY REIMBURSEMENT
In the United States, the Company's products are purchased primarily by
medical institutions, which then bill various third-party payors, such as
Medicare, Medicaid, and other government programs and private insurance plans,
for the health care services provided to patients. Government agencies, private
insurers and other payors determine whether to provide coverage for a particular
procedure and reimburse hospitals for medical treatment at a fixed rate based on
the diagnosis-related group ("DRG") established by the U.S. Healthcare Finance
Administration ("HCFA"). The fixed rate of reimbursement is based on the
procedure performed, and is unrelated to the specific devices used in that
procedure. If a procedure is not covered by a DRG, payors may deny
reimbursement. In addition, some payors may deny reimbursement if they determine
that the device used in a treatment was unnecessary, inappropriate or not
cost-effective, experimental or used for a non-approved indication.
Reimbursement of interventional procedures utilizing the Company's products is
currently covered under a DRG. There can be no assurance that reimbursement for
such procedures will continue to be available, or that future reimbursement
policies of payors will not adversely affect the Company's ability to sell its
products on a profitable basis. Failure by hospitals and other users of the
Company's products to obtain reimbursement from third-party payors, or changes
in government and private
9.
11
third-party payors' policies toward reimbursement for procedures employing the
Company's products, would have a material adverse effect on the Company's
business, financial condition and results of operations. See "Item 7.
Management's Discussion and Analysis of Financial Condition and Results of
Operations--Risk Factors--Limitations on Third-Party Reimbursement."
GOVERNMENT REGULATION
The manufacturing and marketing of the Company's products are subject to
extensive and rigorous government regulation in the United States and in other
countries. The Company believes that its success will be significantly dependent
upon commercial sales of improved versions of its catheter products. The Company
will not be able to market these new products in the United States unless and
until the Company obtains approval or clearance from the FDA. Foreign and
domestic regulatory approvals, if granted, may include significant limitations
on the indicated uses for which a product may be marketed.
If a medical device manufacturer can establish that a newly developed
device is "substantially equivalent" to a legally marketed Class I or Class II
device, or to a Class III device that the FDA has not called for a PMA, the
manufacturer may seek clearance from the FDA to market the device by filing a
premarket notification with the FDA under Section 510(k) of the Federal Food,
Drug, and Cosmetic Act. All of the 510(k) clearances received for the Company's
catheters were based on substantial equivalence to legally marketed devices.
There can be no assurance that 510(k) clearance for any future product or
significant modification of an existing product will be granted or that the
process will not be unduly lengthy. In addition, if the FDA has concerns about
the safety or effectiveness of any of the Company's products, it could act to
withdraw approval or clearances of those products or request that the Company
present additional data. Any such actions would have a material adverse effect
on the Company's business, financial condition and results of operations.
If substantial equivalence cannot be established, or if the FDA determines
that the device or the particular application for the device requires a more
rigorous review to assure safety and effectiveness, the FDA will require that
the manufacturer submit a PMA application that must be reviewed and approved by
the FDA prior to sales and marketing of the device in the United States. The PMA
process is significantly more complex, expensive and time consuming than the
510(k) clearance process and always requires the submission of clinical data. It
is expected that certain of the Company's products under development will be
subject to this PMA process. The Company recently received approval of its PMA
application and, so, can submit PMA supplemental applications to manufacture and
distribute CVD products.
The Company is also required to register as a medical device manufacturer
with the FDA and maintain a license with certain state agencies, such as the
CDHS. As such, the Company is inspected on a routine basis by both the FDA and
the CDHS for compliance with QSR regulations. These regulations require that the
Company manufacture its products and maintain related documentation in a
prescribed manner with respect to manufacturing, testing and control activities.
The Company has also undergone and expects to continue to undergo regular QSR
inspections in connection with the manufacture of its products at the Company's
facilities. Further, the Company is required to comply with various FDA
requirements for labeling. The Medical Device Reporting laws and regulations
require that the Company provide information to the FDA on deaths or serious
injuries alleged to have been associated with the use of its devices, as well as
product malfunctions that would likely cause or contribute to death or serious
injury if the malfunction were to recur. In addition, the FDA prohibits an
approved device from being marketed for unapproved applications. CVD has
received FDA approval to market the FACT and ARC catheters, which utilize the
FOCUS technology, for coronary balloon angioplasty. These catheters are marketed
outside the United States for use in stent deployment. However, without specific
FDA approval for stent deployment, these catheters may not be marketed by the
Company in the United States for such use.
Failure to comply with applicable regulatory requirements can, among other
consequences, result in fines, injunctions, civil penalties, suspensions or loss
of regulatory approvals, product recalls, seizure of products, operating
restrictions and criminal prosecution. In addition, government regulations may
be established in the future that could prevent or delay regulatory clearance or
approval of the Company's products. Delays in receipt of clearances or
approvals, failure to receive clearances or approvals or the loss of previously
received clearances or approvals would have a material adverse effect on the
Company's business, financial condition and results of operations.
10.
12
The Company is also subject to other federal, state and local laws,
regulations and recommendations relating to safe working conditions, laboratory
and manufacturing practices. The extent of government regulation that might
result from any future legislation or administrative action cannot be accurately
predicted. Failure to comply with regulatory requirements could have a material
adverse effect on the Company's business, financial condition and results of
operations.
International sales of the Company's products are subject to the
regulatory requirements in many countries. The regulatory review process varies
from country to country and may in some cases require the submission of clinical
data. The Company typically relies on its distributors in such foreign countries
to obtain the requisite regulatory approvals. There can be no assurance,
however, that such approvals will be obtained on a timely basis or at all. In
addition, the FDA must approve the export to certain countries of devices that
require a PMA but are not yet approved domestically.
Generally, in order to continue selling its products within the European
Economic Area and Switzerland following June 14, 1998, the Company will be
required to achieve compliance with the requirements of the Medical Devices
Directive ("MDD") and affix CE marking on its products to attest to such
compliance; the Company believes that products which have already been delivered
to distributors will be able to continue to be sold by such distributors during
a subsequent three-year transition period. To achieve compliance, the Company's
products must meet the "Essential Requirements" of the MDD relating to safety
and performance and the Company must successfully undergo verification of its
regulatory compliance ("conformity assessment") by a Notified Body selected by
the Company. The Company has selected TUV Product Service of Munich, Germany as
its Notified Body. The nature of such assessment depends on the regulatory class
of the product, and the many of the Company's coronary products are currently in
Class III, the highest risk class, and therefore subject to the most rigorous
controls.
In December 1996, the Company received ISO 9001/EN46001 certification from
its Notified Body with respect to the manufacturing of all of its products,
except the Synthesis coronary stent products. This certification applies to the
manufacturing operations in the Company's Irvine facilities and its contracted
manufacturing facility in Nieuwegein, Netherlands. In January 1998, the Company
obtained the right to affix CE marking to all of its products currently sold in
all countries of the European Economic Area and Switzerland. The Company will be
subject to continued supervision by its Notified Body and will be required to
report any serious adverse incidents to the appropriate authorities. The Company
also will be required to comply with additional national requirements that are
beyond the scope of the MDD. With respect to products not already cleared for CE
marking, the Company will need to comply with the CE marking requirements prior
to June 14, 1998, or else it will be unable to sell such additional products in
the European Economic Area or Switzerland unless and until compliance is
achieved. Failure to achieve such compliance could have a material adverse
effect upon the Company's business, financial condition and results of
operations. There can be no assurance that the Company will be able to achieve
or maintain compliance required for CE marking on all or any of its products or
that it will be able to timely and profitably produce its products while
complying with the requirements of the MDD and other regulatory requirements.
PRODUCT LIABILITY
The Company faces the risk of financial exposure to product liability
claims. The Company's products are often used in situations in which there is a
high risk of serious injury or death. Such risks will exist even with respect
tothose products that have received, or in the future may receive, regulatory
approval for commercial sale. The Company is currently covered under a product
liability insurance policy with coverage limits of $2.0 million per occurrence
and $2.0 million per year in the aggregate. There can be no assurance that the
Company's product liability insurance is adequate or that such insurance
coverage will remain available at acceptable costs. There can be no assurance
that the Company will not incur significant product liability claims in the
future. A successful claim brought against the Company in excess of its
insurance coverage could have a material adverse effect on the Company's
business, financial condition and results of operations. Additionally, adverse
product liability actions could negatively affect the reputation and sales of
the Company's products and the Company's ability to obtain and maintain
regulatory approval for its products, and could substantially divert the time
and effort of management away from the Company's operations.
11.
13
EMPLOYEES
As of December 31, 1997, the Company had 139 employees, including 70 in
manufacturing, 34 in research, development and regulatory affairs, 26 in sales
and marketing and 9 in administration. The Company believes that the success of
its business will depend, in part, on its ability to attract and retain
qualified personnel. The Company believes it has good relations with its
employees.
ITEM 2. PROPERTIES
PROPERTIES
Currently, the Company leases facilities aggregating approximately 35,000
square feet in Irvine, California under lease agreements which expire beginning
in 1998. The Company is currently negotiating an agreement with the lessor to
extend the Irvine leases for at least three years. It also leases approximately
1,800 square feet in Bonn, Germany. The Company believes its facilities are
adequate to meet its requirements through mid-1999.
ITEM 3. LEGAL PROCEEDINGS
There are no material legal proceedings pending.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
None.
12.
14
EXECUTIVE OFFICERS OF THE REGISTRANT
The executive officers and key employees of the Company, and their ages as
of March 1, 1998, are as follows:
NAME AGE POSITION
- ---- --- --------
Michael R. Henson........... 52 Chief Executive Officer and Chairman of the Board of Directors
Jeffrey F. O'Donnell........ 38 President and Chief Operating Officer
Edward A. McDonald.......... 57 Vice President, Advanced Technologies
Dana P. Nickell............. 48 Vice President, Finance and Administration, Chief Financial Officer
Jeffrey H. Thiel............ 42 Vice President, Operations
Claire K. Walker............ 51 Vice President, Clinical Affairs
BACKGROUND
The principal occupations of each executive officer and key employee of
the Company for at least the last five years are as follows:
Michael R. Henson joined the Company as President and Chief Executive
Officer in February 1995. Prior to joining CVD, Mr. Henson served as the Chief
Executive Officer of EndoSonics from 1988 to February 1995. He was appointed
Chairman of the Board of Directors of EndoSonics in February 1993. Between April
1983 and February 1988, Mr. Henson served as President and Chief Executive
Officer of Trimedyne, Inc., a manufacturer of medical lasers and catheters.
Prior to joining Trimedyne in 1983, Mr. Henson held positions as Vice President
for G.D. Searle & Company, Director of Marketing for the Hospital Products
Division of Abbott Laboratories, and Marketing Manager for Bristol Myers and
Company.
Jeffrey F. O'Donnell has served as President and Chief Operating Officer
since August 1997. He joined CVD as Vice President, Sales & Marketing in
November 1995. Prior to joining CVD, Mr. O'Donnell served as President and Vice
President of Marketing and Business Development of Kensey Nash Corporation, a
medical device manufacturer, from January 1994 to May 1995. From 1988 to 1994,
Mr. O'Donnell held various sales and regional management positions at ACS. Prior
to working at ACS, Mr. O'Donnell held senior sales and marketing positions with
Boston Scientific and Johnson & Johnson.
Edward A. McDonald became Vice President of Advanced Technologies in
January 1998. From May 1997 to January 1998 he was Vice President of Interpoint
Products. He joined CVD in October 1996 as Project Director working on the Self
Expanding Microporous Stent project. Before coming to CVD, Mr. McDonald was
Founder, President and Chief Executive Officer of Intraluminal Devices, Inc., a
medical device developer of vascular stent technology from September 1995 to
October 1996. From September 1993 to September 1995 he served as President and
Chief Executive Officer of McDonald Medical, a consulting company. Mr. McDonald
was President & Chief Executive Officer of Laparomed Corporation, a medical
device developer of laproscopic instruments from October 1990 to September 1993.
Dana P. Nickell joined the Company as Vice President, Finance and
Administration and Chief Financial Officer in December 1995 and was appointed
Secretary in May 1996. Prior to joining CVD, he was Chief Financial Officer of
Innerspace Inc., a medical device manufacturer which filed for bankruptcy
protection in 1995, from May 1994 to April 1995. From August 1993 until April
1994, Mr. Nickell served as Chief Financial Officer of Masimo Corporation, a
developer of pulse oximeter technology. Between November 1988 and June 1993, Mr.
Nickell was Chief Financial Officer and Vice President, Finance, Administration
and Business Development of EndoSonics. He also served as Secretary of
EndoSonics from January 1990 to August 1992. Mr. Nickell is a Certified Public
Accountant.
Jeffrey H. Thiel has served as Vice President, Operations since October
1996. Prior to joining CVD, Mr. Thiel served as Director of Operations of BEI
Medical Systems from May 1995 to October 1996. From July 1989 to November 1994,
Mr. Thiel held various Manufacturing and Operation Management positions with St.
Jude Medical.
13.
15
Claire K. Walker has served as Vice President of Clinical Affairs since
April 1997. She joined the Company in November 1994 as Director of Clinical
Affairs. From May 1992 to November 1994, Ms. Walker provided clinical marketing
consulting services to CVD. From September 1990 to November 1992, Ms. Walker
served as a principal of CKW and Associates providing project specific
consulting services to InterVentional Technologies, Inc., a medical device
company.
14.
16
PART II
ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS.
The Company's Common Stock commenced trading on the Nasdaq National Market
on June 20, 1996 and is traded under the symbol "CCVD". The following table sets
forth for the periods indicated the high and low sale prices for the Common
Stock as reported on the Nasdaq National Market.
HIGH LOW
---- ---
FISCAL 1996
Second Quarter $12 3/4 $10 1/2
Third Quarter 17 1/2 10 1/4
Fourth Quarter 17 1/2 9 5/8
FISCAL 1997
First Quarter $13 1/4 $7 1/2
Second Quarter 10 1/4 6 5/8
Third Quarter 9 3/8 6 5/8
Fourth Quarter 8 4 3/4
On March 4, 1998, the closing sale price of the Common Stock as reported
on the Nasdaq National Market was $4.50 per share. As of March 4, 1998, there
were approximately 292 holders of record of the Common Stock.
SALES OF UNREGISTERED SECURITIES
In July 1997, the Company sold approximately 25,000 shares of its common
stock to certain principals of Cathex at $7.94 per share, for an aggregate
purchase price of $200,000. The securities were sold pursuant to an exemption
from registration under Section 4(2) of the Securities Act of 1933, as amended.
USE OF PROCEEDS
The Company has used approximately $2.7 million of the net proceeds from
the initial public offering ("IPO") for repayment of certain outstanding
indebtedness to EndoSonics, Inc., a holder of in excess of ten percent of the
Common Stock of the Company. From the date of the IPO until September 30, 1997,
in the normal course of business, the Company has paid salaries and bonuses in
excess of $0.1 million each to six officers of the Company and used $4.2 million
for working capital. The Company has also used approximately $1.4 million of the
net proceeds for machinery and equipment and leasehold improvement purchases.
From August 1997 to December 1997, the Company used approximately $2.2 million
to repurchase 345,000 shares of the Company's Common Stock. At December 31,
1997, approximately $31.0 million was held in temporary investments, of which
approximately $5.0 million is invested in U.S. Treasury and other agencies debt
securities and $26.0 million is invested in corporate debt securities.
DIVIDEND POLICY
The Company has not paid dividends since its inception. The Company
currently intends to retain all earnings, if any, for use in the expansion of
its business and therefore does not anticipate paying any dividends in the
foreseeable future.
15.
17
ITEM 6. SELECTED FINANCIAL DATA.
YEAR ENDED DECEMBER 31,
------------------------------------------------------------------------
1993(1) 1994 1995 1996 1997
-------- -------- -------- -------- --------
(In thousands)
Consolidated Statement of Operations
Data:
Revenue:
Sales $ 126 $ 1,169 $ 3,462 $ 8,384 $ 11,332
License fee and other from related
party -- 1,000 -- 150 --
Contract -- 220 641 200 --
-------- -------- -------- -------- --------
Total revenue 126 2,389 4,103 8,734 11,332
Costs and expenses:
Cost of sales 79 848 2,051 4,111 6,418
Charge for acquired in-process research
and development(2) 2,001 -- 488 2,133 --
Research and development 734 1,228 1,683 3,582 7,041
Marketing and sales 94 748 1,526 3,358 6,691
General and administrative 96 587 1,331 1,548 2,179
-------- -------- -------- -------- --------
Total operating costs and expenses 3,004 3,411 7,079 14,732 22,329
-------- -------- -------- -------- --------
Loss from operations (2,878) (1,022) (2,976) (5,998) (10,997)
Other income 29 51 102 1,374 2,225
-------- -------- -------- -------- --------
Net loss $ (2,849) $ (971) $ (2,874) $ (4,624) $ (8,772)
======== ======== ======== ======== ========
Basic and diluted net loss per share
(proforma through June 1996)(3) $ (0.28) $ (0.71) $ (0.69) $ (0.96)
======== ======== ======== ========
Shares used in computing basic and diluted
net loss per share (proforma through
June 1996)(3) 3,487 4,052 6,755 9,118
======== ======== ======== ========
DECEMBER 31,
------------------------------------------------------------------------
1993 1994 1995 1996 1997
-------- -------- -------- -------- --------
(In thousands)
CONSOLIDATED BALANCE SHEET DATA:
Cash and cash equivalents $ 547 $ 3,379 $ 1,568 $ 17,192 $ 6,141
Marketable securities available-for-sale -- -- -- 25,733 24,773
Working capital (deficit) (75) 1,366 (774) 46,142 33,828
Total assets 690 4,340 4,002 50,084 41,361
Convertible obligation -- -- 750 -- --
Accumulated deficit (2,580) (3,551) (6,425) (11,049) (19,821)
Total stockholders' equity (net capital deficiency) $ (241) $ 1,288 $ (1,098) $ 47,623 $ 37,873
(1) The period from January 1, 1993 to June 9, 1993 reflects the operations of
the predecessor to the Company. See Note 1 of Notes to Consolidated
Financial Statements.
(2) The charge for acquired in-process research and development reflects a
change in the basis of the Company's assets and liabilities as a result of
the acquisition by EndoSonics which has been allocated to the Company for
the years ended December 31, 1993 and 1995 and the excess of the purchase
price for Intraluminal Devices, Inc. and the associated acquisition
expenses for the year ended December 31, 1996. See Notes 1 and 2 of Notes
to Consolidated Financial Statements.
(3) The per share amounts prior to 1997 have been restated as required to
comply with Statement of Financial Accounting Standards No. 128, Earnings
Per Share. See Note 1 of Notes to Consolidated Financial Statements for
further information.
16.
18
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS.
This Annual Report on Form 10-K contains forward looking statements which
involve risks and uncertainties. The Company's actual results may differ
significantly from the results discussed in the forward-looking statements.
Factors that might cause such a difference include, but are not limited to,
those discussed in "Risk Factors" beginning on page 20.
OVERVIEW
CVD designs, develops, manufactures and markets catheters, stents and related
products used to treat certain vascular diseases. The Company's patented
catheters utilize its Focus and M3 technologies to deliver therapeutic radial
pressure, stents, drugs or contrast media and improved blood flow during
angioplasty and stent placement procedures. To date, the majority of the
Company's revenue has been derived from sales of its angioplasty and
angioplasty-related catheters.
From inception (March 16, 1992) through the first quarter of 1994, the Company's
operations were limited and consisted primarily of research and development and
other start-up activities. On June 15, 1992, EndoSonics acquired a 40% interest
in CVD in exchange for $0.5 million in cash. Pursuant to an Agreement and Plan
of Reorganization between EndoSonics and CVD signed on June 9, 1993, EndoSonics
acquired all of the outstanding capital stock of CVD in exchange for $0.3
million in cash and 250,000 shares of EndoSonics' Common Stock with an aggregate
market value of $1.6 million. The acquisition by EndoSonics resulted in a new
basis for CVD's assets and liabilities. Accordingly, the purchase price paid by
EndoSonics has been allocated to CVD's identifiable assets and liabilities,
including $2.0 million to acquired in-process research and development, which
was immediately expensed, as no CVD products had received regulatory approval
and the technology did not have alternative future uses. Pursuant to the terms
of the Agreement and Plan of Reorganization, in June 1995, EndoSonics became
obligated to issue 50,000 shares of its Common Stock with an aggregate market
value of $0.5 million, to the former shareholders of CVD because the market
price of EndoSonics' stock did not exceed a specified price for a specified
period during the two-year period following the acquisition. The fair value of
such shares was charged to acquired in-process technology. In March 1996,
EndoSonics purchased 400,000 shares of CVD's Series B Preferred Stock for a
purchase price of $8.0 million, which converted into 800,000 shares of Common
Stock upon the consummation of the initial public offering.
In September 1994, CVD and SCIMED, which is now a unit of Boston Scientific
Corporation, entered into a Stock Purchase and Technology License Agreement to
develop and license CVD's patented combination balloon angioplasty/site-specific
drug delivery technology (the Transport product line) for use in the coronary
vessels. Through December 31, 1996 the Company had received in the aggregate
approximately $2.2 million in license fees, research and development funding and
technical assistance from SCIMED under this agreement. The Company received no
revenues from SCIMED in 1997. In 1994, SCIMED also purchased a 19% equity
position in the Company for a purchase price of $2.5 million. In August 1997,
SCIMED exercised warrants to purchase 120,000 shares of CVD's common stock at a
price of $3.29 per share. See "Item 1. Business--Strategic Relationships."
In January 1995, the Company and ACS entered into an agreement pursuant to which
the Company acquired certain rights to ACS' SmartNeedle Technology, subject to
the payment of certain royalties. The parties subsequently confirmed their
understanding with respect to certain matters in a second agreement dated March
4, 1996 (collectively, the "ACS Agreements"). Pursuant to the ACS Agreements,
ACS was granted the option to acquire the exclusive worldwide rights to certain
CVD perfusion technology, which ACS exercised on February 14, 1996. In exchange
for this perfusion technology, ACS is obligated to make milestone and minimum
annual royalty payments to CVD, and also has certain obligations to develop and
market the perfusion technology. Through December 31, 1996 the Company had
received approximately $0.35 million in milestone payments under the ACS
Agreements. The Company received no payments during 1997. In February 1998, the
partners agreed to terminate the perfusion technology Agreement. See "Item 1.
Business--Strategic Relationships."
The Company currently sells its products through a combination of medical device
distributors and a limited number of direct sales personnel. The Company is a
party to three agreements for the U.S. distribution of products
17.
19
incorporating its Focus and M3 technologies. CVD distributed certain products in
Japan through an exclusive distribution agreement with Fukuda which was
terminated and replaced by the Company in May 1997 with a similar agreement with
Cathex. CVD also has distribution agreements with 30 companies covering 35
countries outside the United States and Japan. See "Item 1. Business --Strategic
Relationships."
On July 15, 1996, the Company entered into co-distribution agreements with
Medtronic, providing for the co-distribution of the Company's FACT, CAT and ARC
balloon angioplasty catheters. Under the terms of these agreements, Medtronic
purchased a minimum number of angioplasty catheters manufactured by the Company
for distribution worldwide for a period of up to three years. Specific products
to be distributed by Medtronic would differ in individual country markets. The
initial term of the Medtronic agreements was for a period of three years from
the date of first delivery of a product. In May 1997, Medtronic advised the
Company of its election to not make minimum purchases of product for the second
year of the agreement. In June 1997, Medtronic informed CVD that it would not
fulfill its commitment for the first year of the agreement and that it did not
believe it was required to fulfill such commitment. This dispute adversely
affected the Company's financial results for the second half of 1997 in that
Medtronic did not fulfill its commitment to purchase an additional $1,300,000 in
products. See "Item 1. Business--Strategic Relationships."
RESULTS OF OPERATIONS
Years Ended December 31, 1996 and December 31, 1997
Sales Revenue. Sales revenue increased to $11.3 million in 1997 from $8.4
million in 1996, representing an increase of 35%. The increase resulted
primarily from increased sales of the Company's Focus catheters, and, to a
lesser extent, the introduction of new coronary stent products. Sales of
products through Medtronic under the Company's co-exclusive distribution
agreement and sales of products in Japan through the Company's exclusive
distribution relationships with Fukuda and Cathex accounted for 7 % and 13 %,
respectively, of total product sales in 1997. The Agreements with Medtronic and
Fukuda were terminated in 1997. See "Item 1. Business--Strategic Relationships."
License Fee and Other Revenue. There were no license fees or other revenues from
ACS in 1997, compared with $0.2 million in 1996. In February of 1998, ACS
elected to terminate the technology license agreement with the Company. See
"Item 1. Business--Strategic Relationships."
Contract Revenue. There were no contract revenues from SCIMED in 1997, compared
with $0.2 million in 1996. See "Item 1. Business--Strategic Relationships."
Cost of Sales. Cost of sales increased to $6.4 million in 1997 from $4.1 million
in 1996. This increase resulted primarily from increased manufacturing volumes
related to increased product sales and reserves and allowances of approximately
$1.0 million for excess product inventories. The increase in the allowance for
excess inventories resulted from increased product manufactured for sales
forecasts which were subsequently lowered and unfulfilled purchase commitments.
The Company considered remaining shelf life and anticipated sales volumes in
determining the amount of allowance needed.
Charge for Acquired In-process Research and Development. The Company incurred a
charge of $2.1 million in 1996 in connection with the acquisition of
Intraluminal Devices, Inc. ("IDI"). The excess of the purchase price of IDI over
the fair market value of the net assets acquired was recorded as in-process
research and development. The acquired in-process research and development was
immediately written off as IDI was in the development stage and had not yet
received regulatory approval for any of its products at the time of the
acquisition. There were no similar charges in 1997.
Research and Development. Research and development increased to $7.0 million in
1997 compared to $3.6 million in 1996, representing an increase of 97%. This
increase resulted primarily from expenditures on the development of Focus
technology, vascular stents and vascular access products. The Company believes
it must maintain a substantial commitment to research and development to remain
competitive and expects expenditures related to research and development to
increase.
Marketing and Sales. Marketing and sales expenses increased to $6.7 million in
1996 from $3.4 million in 1996, representing an increase of 99%. This increase
resulted mainly from the expansion of the Company's direct sales force in the
United States and marketing expenses related to the product launch of the
coronary stent products in
18.
20
foreign markets. The Company expects to expand and expects expenses associated
with these activities to increase in the future as it expands.
General and administrative. General and administrative expenses increased to
$2.2 million in 1997 from $1.5 million in 1996, representing an increase of 41%.
The added costs were primarily due to additions in administrative staff and the
added costs of operating as a public company for an entire year. The Company
began trading as a public company on June 20, 1996.
Other Income. Other income, principally interest income, increased to $2.2
million in 1997 from $1.4 million in 1996. The 62% increase primarily resulted
from the investment of the net proceeds of the Company's initial public offering
for the entire year of 1997.
Years Ended December 31, 1995 and December 31, 1996
Sales Revenue. Sales revenue increased to $8.4 million in 1996 from $3.5 million
in 1995, representing an increase of 140%. The increase resulted primarily from
increased sales of the Company's Focus catheters, and, to a lesser extent, the
introduction of new products. Sales of products through Medtronic under the
Company's co-exclusive distribution agreement and sales of products in Japan
through the Company's exclusive distribution relationship with Fukuda accounted
for 22% and 15%, respectively, of total product sales in 1996.
License Fee and Other Revenue. License fee and other revenue from ACS remained
constant at $0.2 million in both 1996 and 1995. See "Item 1. Business--Strategic
Relationships."
Contract Revenue. Contract Revenue was $0.2 million in 1996 and $0.6 in 1995.
This decrease stemmed from reduced technology development and other support from
SCIMED. See "Item 1. Business--Strategic Relationships."
Cost of Sales. Cost of sales increased to $4.1 million in 1996 from $2.1 million
in 1995. This increase resulted primarily from increased manufacturing volumes
related to increased product sales. In July 1995, the Company transferred its
product manufacturing from EndoSonics' facility to the Company's facility in
Irvine, California.
Charge for Acquired In-process Research and Development. The Company incurred a
charge of $2.1 million in 1996 in connection with the acquisition of
Intraluminal Devices, Inc. ("IDI"). The excess of the purchase price of IDI over
the fair market value of the net assets acquired was recorded as in-process
research and development. The acquired in-process research and development was
immediately written off as IDI was in the development stage and had not yet
received regulatory approval for any of its products at the time of the
acquisition.
Research and Development. Research and development increased to $3.6 million in
1996 compared to $1.7 million in 1995, representing an increase of 112%. This
increase resulted primarily from expenditures on the development of vascular
access and Focus technology products. The Company believes it must maintain a
substantial commitment to research and development to remain competitive and
expects expenditures related to research and development to increase.
Marketing and Sales. Marketing and sales expenses increased to $3.4 million in
1996 from $1.5 million in 1995, representing an increase of 127%. This increase
resulted mainly from the expansion of the Company's direct sales force in the
United States and marketing expenses related to the product launch of the FACT
and ARC catheters. The Company expects to expand and expects expenses associated
with these activities to increase in the future as it expands.
General and administrative. General and administrative expenses increased to
$1.5 million in 1996 from $1.3 million in 1995, representing an increase of 15%.
The added costs were primarily due to additions in administrative staff and the
added costs of operating as a public company.
Other Income. Other income, principally interest income, increased to $1.3
million in 1996 from $0.1 million in 1995. The increase resulted from the
investment of the net proceeds of the Company's initial public offering which
amounted to approximately $42.8 million.
19.
21
The Company has experienced an operating loss for each of the last three years
and expects to continue to incur operating losses through at least 1998. CVD's
results of operations have varied significantly from quarter to quarter.
Quarterly operating results depend upon several factors, including the timing
and amount of expenses associated with expanding the Company's operations, the
conduct of clinical trials and the timing of regulatory approvals, new product
introductions both in the United States and internationally, the mix between
pilot production of new products and full-scale manufacturing of existing
products, the mix between domestic and export sales, variations in foreign
exchange rates, changes in third-party payors' reimbursement policies and
healthcare reform. The Company does not operate with a significant backlog of
customer orders, and therefore revenues in any quarter are significantly
dependent on orders received within that quarter. In addition, the Company
cannot predict ordering rates by distributors, some of whom place infrequent
stocking orders. The Company's expenses are relatively fixed and difficult to
adjust in response to fluctuation revenues. As a result of these and other
factors, the Company expects to continue to experience significant fluctuations
in quarterly operating results, and there can be no assurance that the Company
will be able to achieve or maintain profitability in the future.
LIQUIDITY AND CAPITAL RESOURCES
Since inception, the Company has financed its operations primarily from the sale
of its equity securities, advances from EndoSonics, licensing its technologies
and through international product distribution agreements. Prior to the
Company's initial public offering, the Company had raised an aggregate of
approximately $11.4 million from the private sales of preferred and common stock
and $2.7 million in working capital from EndoSonics, which was repaid to
EndoSonics during the third quarter of 1996. In the third quarter of 1996, the
Company closed its initial public offering of common stock, resulting in net
proceeds of $42.8 million after deducting underwriting discounts and commissions
and other expenses of the offering. For the years ended December 31, 1997, 1996
and 1995, the Company's net cash used in operating activities was $9.8, $ 6.2
million and $2.1 million, respectively. These increases were primarily due to
funding of operating losses and the charges for acquired in-process research and
development.
On December 31, 1997, CVD had cash, cash equivalents and marketable securities
available for sale of $30.9 million. The Company expects to incur substantial
costs related to, among other things, clinical testing, product development,
marketing and sales expenses, and to utilize increased levels of working capital
to finance its accounts receivable and inventories, prior to achieving positive
cash flow from operations. The Company anticipates that its existing capital
resources will be sufficient to fund its operations through June 30, 1999. CVD's
future capital requirements will depend on many factors, including its research
and development programs, the scope and results of clinical trials, the
regulatory approval process, the costs involved in intellectual property rights
enforcement or litigation, competitive products, the establishment of
manufacturing capacity, the establishment of sales and marketing capabilities,
and the establishment of collaborative relationships with other parties. The
Company may need to raise funds through additional financings, including private
or public equity offerings and collaborative arrangements with existing or new
corporate partners. There can be no assurance that funds will be raised on
favorable terms, or at all. If adequate funds are not available, the Company may
be required to delay, scale back or eliminate one or more of its development
programs or obtain funds through arrangements with collaborative partners or
others that may require the Company to grant rights to certain technologies or
products that the Company would not otherwise grant.
RISK FACTORS
History of Operating Losses; Anticipated Future Losses; Future Capital
Requirements. The Company was founded in 1992 and has experienced annual
operating losses since its inception. Its net loss was $8.8 million, $4.6
million and $2.9 million in 1997, 1996 and 1995, respectively. The Company's
accumulated deficit at December 31, 1997 was $19.8 million. The Company expects
to continue to incur operating losses through at least 1998 and there can be no
assurance that the Company will ever be able to achieve or sustain profitability
in the future. The Company expects to incur substantially increased costs
related to, among other things, clinical testing, product development,
manufacturing scale-up and sales and marketing activities. The Company
anticipates that its existing capital resources will be sufficient to fund its
operations through June 30, 1999. The Company's future capital requirements will
depend on many factors, including its research and development programs, the
scope and results of clinical trials, the time and costs involved in obtaining
regulatory approvals, the costs involved in obtaining and enforcing patents or
any litigation by third parties regarding intellectual property, the status of
competitive products, the establishment and
20.
22
scale-up of manufacturing capacity, the establishment of sales and marketing
capabilities, the establishment of collaborative relationships with other
parties and costs related to the acquisition of new technologies and product
development. The Company may require additional funds to finance these
activities and for working capital requirements. The Company may seek such funds
through financings, including private or public equity or debt offerings and
collaborative arrangements with corporate partners. There can be no assurance
that funds will be raised on favorable terms, if at all. If adequate funds are
not available, the Company may be required to delay, scale back or eliminate one
or more of its development programs or obtain funds through arrangements with
collaborative partners or others that may require the Company to relinquish
rights to certain technologies, product candidates or products that the Company
would not otherwise relinquish. See "Item 7. Management's Discussion and
Analysis of Financial Condition and Results of Operations."
Dependence Upon New Products; Rapid Technological Change; Risk of Obsolescence.
The medical device industry generally, and the interventional catheter market in
particular, are characterized by rapid technological change, changing customer
needs, and frequent new product introductions. As a result, the useful lives of
both the technology and products for the treatment of cardiovascular and
peripheral vascular diseases are limited, in some instances to as little as
twelve months. The Company's future success will depend upon its ability to
develop, manufacture and introduce new products that address the needs of its
customers. There can be no assurance that the Company will be successful in
developing and marketing new products that achieve market acceptance or that the
Company will not experience difficulties that could delay or prevent the
successful development, introduction and marketing of new products. In addition,
there can be no assurance that the Company's existing products will not be
rendered obsolete as a result of technological developments or that the products
that the Company has under development will not be rendered obsolete prior to
the introduction of such products. See "Item 1. Business--Products."
Limited Sales to Date; Uncertainty of Market Acceptance. The Company's catheters
and stents are used in conjunction with angioplasty and other intravascular
procedures such as vascular stenting and drug delivery. Although the Company has
received regulatory clearance for a total of 84 product models, only 52 of such
product models have been marketed. Of those products which have been marketed,
many have been marketed only in limited quantities or in certain markets, or are
allowed to be marketed only in certain countries. In addition, while
interventional catheters are widely used technologies, the Company's catheter
designs are relatively new. The commercial success of the Company's products
will depend upon their acceptance by the medical community as useful,
cost-effective components of interventional cardiovascular and peripheral
vascular procedures, including the acceptance by the medical community of stents
and the availability and acceptance of therapeutic drugs for use in
interventional procedures. The Company currently relies upon relationships with
certain prominent doctors and researchers in the medical community to promote
the uses and acceptance of its approved products. There can be no assurance that
the Company will be able to maintain such relationships or establish additional
relationships in the future. The erosion or loss of any such relationship could
detrimentally affect the market acceptance of the Company's products. Failure of
the Company's products to achieve such market acceptance would have a material
adverse effect on the Company's business, financial condition and results of
operations. See "Item 1. Business--Products."
Fluctuations in Quarterly Operating Results. CVD's results of operations have
varied significantly from quarter to quarter. The Company has experienced an
operating loss for each of the last six years. Quarterly operating results will
depend upon several factors, including the timing and amount of expenses
associated with expanding the Company's operations, the conduct of clinical
trials and the timing of regulatory approvals, new product introductions both in
the United States and internationally, the mix between pilot production of new
products and full-scale manufacturing of existing products, the mix between
domestic and export sales, variations in foreign exchange rates, changes in
third-party payors' reimbursement policies and healthcare reform. The Company
does not operate with a significant backlog of customer orders, and therefore
revenues in any quarter are significantly dependent on orders received within
that quarter. In addition, the Company cannot predict ordering rates by
distributors, some of whom place infrequent stocking orders. The Company's
expenses are relatively fixed and difficult to adjust in response to fluctuating
revenues. As a result of these and other factors, the Company expects to
continue to experience significant fluctuations in quarterly operating results,
and there can be no assurance that the Company will be able to achieve or
maintain profitability in the future. See "Item 7. Management's Discussion and
Analysis of Financial Condition and Results of Operations."
21.
23
Reliance on Patents and Proprietary Technology; Risk of Patent Infringement.
While the Company owns certain issued and allowed U.S. patents and has
additional U.S. and foreign patent applications pending, there can be no
assurance that the Company's patent applications will issue as patents or that
any issued patents will provide competitive advantages for the Company's
products or will not be successfully challenged or circumvented by its
competitors. The interventional cardiovascular and peripheral vascular markets
in general and the market for balloon angioplasty catheters and coronary stents
(including the types of catheters and stents offered by CVD) in particular has
been characterized by substantial litigation regarding patent and other
intellectual property rights. There can be no assurance that the Company's
products do not infringe such patents or rights. During 1997, the Company was
sued for trademark infringement regarding the Company's use of the product name
"Lynx" in connection with one of the Company's balloon angioplasty catheter
product lines. CVD paid no monetary damages but agreed to a consent judgment
which prohibits the Company from using this name in the United States.
In the event that any parties assert claims against the Company for patent
infringement and such patents are upheld as valid and enforceable, the Company
could be prevented from utilizing the subject matter claimed in such patents, or
would be required to obtain licenses from the owners of any such patents or
redesign its products or processes to avoid infringement. There can be no
assurance that such licenses would be available or, if available, would be so on
terms acceptable to the Company or that the Company would be successful in any
attempt to redesign its products or processes to avoid infringement. In
addition, foreign intellectual property laws may not provide protection
commensurate with that provided by U.S. intellectual property laws, and there
can be no assurance that foreign intellectual property laws will adequately
protect the Company's intellectual property rights abroad. The Company also
relies on trade secrets and proprietary technology and enters into
confidentiality and non-disclosure agreements with its employees, consultants
and advisors. There can be no assurance that the confidentiality of such trade
secrets or proprietary information will be maintained by employees, consultants,
advisors or others, or that the Company's trade secrets or proprietary
technology will not otherwise become known or be independently developed by
competitors in such a manner that the Company has no practical recourse.
Litigation may be necessary to defend against claims of infringement or
invalidity, to enforce patents issued to the Company or to protect trade
secrets, and there can be no assurance that any such litigation would be
successful. Any litigation could result in substantial costs to, and diversion
of resources by, the Company and its officers, which could have a material
adverse effect on the Company's business, financial condition and results of
operations. See "Item 1. Business--Patents and Proprietary Information."
Significant Competition. Competition in the market for devices used in the
treatment of cardiovascular and peripheral vascular disease is intense, and is
expected to increase. The interventional cardiology market is characterized by
rapid technological innovation and change, and the Company's products could be
rendered obsolete as a result of future innovations. The Company's catheters,
coronary stents and other products under development compete or will compete
with products marketed by a number of manufacturers, including Advanced
Cardiovascular Systems, Inc., a subsidiary of Guidant Corporation ("ACS"),
SCIMED Life Systems, Inc., a subsidiary of Boston Scientific Corporation
("SCIMED"), Johnson & Johnson Interventional Systems ("JJIS") and Cordis
Corporation, subsidiaries of Johnson & Johnson, Medtronic, Inc., C.R. Bard, Inc.
and Schneider USA, a subsidiary of Pfizer, Inc. Such companies have
significantly greater financial, management and other resources, established
market positions, and significantly larger sales and marketing organizations
than does the Company. The Company also faces competition from manufacturers of
other catheter-based devices, vascular stents and pharmaceutical products
intended to treat vascular disease. In addition, the Company believes that many
of the customers and potential customers of the Company's products prefer to
purchase catheter and stent products from a single source. Accordingly, many of
the Company's competitors, because of their size and range of product offerings,
have a competitive advantage over the Company. There can be no assurance that
the Company's competitors will not succeed in developing or marketing
technologies or products that are more clinically effective or cost effective
than any that are being marketed or developed by the Company, or that such
competitors will not succeed in obtaining regulatory approval for introducing or
commercializing any such products prior to the Company. See "Item 1.
Business--Competition."
Limited Manufacturing Experience. The Company's success will depend in part on
its ability to manufacture its products in compliance with ISO 9001, the FDA's
QSR requirements, California Department of Health Services ("CDHS") licensing
and other regulatory requirements, in sufficient quantities and on a timely
basis, while maintaining product quality and acceptable manufacturing costs. The
Company began manufacturing certain of its products at its facilities in July
1995. The Company also introduced a significant number of new products in 1996
22.
24
and 1997. Accordingly, the Company has limited experience in manufacturing its
products. The Company has undergone and expects to continue to undergo regular
QSR inspections in connection with the manufacture of its products at the
Company's facilities. The Company's success will depend, among other things, on
its ability to efficiently manage the simultaneous manufacture of different
products and to integrate the manufacture of new products with existing
products. There can be no assurance that the Company will not encounter
difficulties in scaling up production of new products, including problems
involving production yields, quality control and assurance, component supply and
shortages of qualified personnel. The Company's failure to successfully commence
the manufacturing of these new products, or to increase production volumes of
new or existing products in a timely manner, would materially adversely affect
the Company's business, financial condition and results of operations. Failure
to increase production volumes in a timely or cost-effective manner or to
achieve or maintain compliance with ISO 9001, QSR requirements, CDHS licensing
or other regulatory requirements could have a material adverse effect on the
Company's business, financial condition and results of operations.
The Company purchases many standard and custom built components from independent
suppliers and subcontracts certain manufacturing processes from independent
vendors. Most of these components and processes are available from more than one
vendor. However, certain manufacturing processes are currently performed by
single vendors. An interruption of performance by any of these vendors could
have a material adverse effect on the Company's ability to manufacture its
products until a new source of supply was qualified and, as a result, could have
an adverse effect on the Company's business, financial condition and results of
operations. See "Item 1. Business--Manufacturing" and "Item 1.
Business--Government Regulation."
Potential Inability to Manage Growth. Prior to June 1996, the Company
historically relied on EndoSonics to perform certain activities on its behalf,
including manufacturing, financial, regulatory and administrative functions.
Since July 1995, CVD has conducted its manufacturing operations at its
facilities in Irvine and also currently performs the financial, regulatory and
administrative functions previously performed by EndoSonics. Accordingly, the
Company has experienced a period of significant expansion of its operations that
has placed a significant strain upon its management systems and resources. The
Company has implemented a number of new financial and management controls,
reporting systems and procedures. The Company also plans to expand the
geographic scope of its customer base and operations. This expansion has
resulted and will continue to result in substantial demands on the Company's
management resources. The Company's ability to manage future expansion of its
operations will require the Company to continue to improve its financial and
management controls, reporting systems and procedures on a timely basis and to
expand, train and manage its employee work force. There can be no assurance that
the Company will be able to do so successfully. The failure to do so would have
a material adverse effect on the Company's business, financial condition and
results of operations.
Government Regulation. The manufacturing and marketing of the Company's products
are subject to extensive and rigorous government regulation in the United States
and in other countries. The Company believes that its success will be
significantly dependent upon commercial sales of improved versions of its
catheter and coronary stent products. The Company will not be able to market
these new products in the United States unless and until the Company obtains
approval or clearance from the FDA. Foreign and domestic regulatory approvals,
if granted, may include significant limitations on the indicated uses for which
a product may be marketed.
If a medical device manufacturer can establish that a newly developed device is
"substantially equivalent" to a legally marketed Class I or Class II device, or
to a Class III device that the FDA has not called for a premarket approval
("PMA"), the manufacturer may seek clearance from the FDA to market the device
by filing a premarket notification with the FDA under Section 510(k) of the
Federal Food, Drug, and Cosmetic Act ("510(k)"). All of the 510(k) clearances
received for the Company's catheters were based on substantial equivalence to
legally marketed devices. There can be no assurance that 510(k) clearance for
any future product or significant modification of an existing product will be
granted or that the process will not be unduly lengthy. In addition, if the FDA
has concerns about the safety or effectiveness of any of the Company's products,
it could act to withdraw approval or clearances of those products or request
that the Company present additional data. Any such actions would have a material
adverse effect on the Company's business, financial condition and results of
operations.
If substantial equivalence cannot be established, or if the FDA determines that
the device or the particular application for the device requires a more rigorous
review to assure safety and effectiveness, the FDA will require that the
23.
25
manufacturer submit a PMA application that must be reviewed and approved by the
FDA prior to sales and marketing of the device in the United States. The PMA
process is significantly more complex, expensive and time consuming than the
510(k) clearance process and always requires the submission of clinical data. It
is expected that certain of the Company's products under development will be
subject to this PMA process. In February 1998, the FDA approved the Company's
PMA application and, so, the Company can now independently seek approval of its
products.
The Company is also required to register as a medical device manufacturer with
the FDA and maintain a license with certain state agencies, such as the CDHS. As
such, the Company is inspected on a routine basis by both the FDA and the CDHS
for compliance with QSR requirements. These regulations require that the Company
manufacture its products and maintain related documentation in a prescribed
manner with respect to manufacturing, testing and control activities. The
Company has also undergone and expects to continue to undergo regular QSR
inspections in connection with the manufacture of its products at the Company's
facilities. Further, the Company is required to comply with various FDA
requirements for labeling. The Medical Device Reporting laws and regulations
require that the Company provide information to the FDA on deaths or serious
injuries alleged to have been associated with the use of its devices, as well as
product malfunctions that would likely cause or contribute to death or serious
injury if the malfunction were to recur. In addition, the FDA prohibits an
approved device from being marketed for unapproved applications. CVD has
received FDA approval to market the FACT and ARC catheters, which utilize the
Focus technology, for coronary balloon angioplasty. These catheters are marketed
outside the United States for use in stent deployment. However, without specific
FDA approval for stent deployment, these catheters may not be marketed by the
Company in the United States for such use.
Failure to comply with applicable regulatory requirements can, among other
consequences, result in fines, injunctions, civil penalties, suspensions or loss
of regulatory approvals, product recalls, seizure of products, operating
restrictions and criminal prosecution. In addition, government regulations may
be established in the future that could prevent or delay regulatory clearance or
approval of the Company's products. Delays in receipt of clearances or
approvals, failure to receive clearances or approvals or the loss of previously
received clearances or approvals would have a material adverse effect on the
Company's business, financial condition and results of operations.
The Company is also subject to other federal, state and local laws, regulations
and recommendations relating to safe working conditions, laboratory and
manufacturing practices. The extent of government regulation that might result
from any future legislation or administrative action cannot be accurately
predicted. Failure to comply with regulatory requirements could have a material
adverse effect on the Company's business, financial condition and results of
operations. See "Item 1. Business--Products" and "Item 1. Business--Government
Regulation."
International sales of the Company's products are subject to the
regulatory requirements in many countries. The regulatory review process varies
from country to country and may in some cases require the submission of clinical
data. The Company typically relies on its distributors in such foreign countries
to obtain the requisite regulatory approvals. There can be no assurance,
however, that such approvals will be obtained on a timely basis or at all. In
addition, the FDA must approve the export to certain countries of devices that
require a PMA but are not yet approved domestically.
Generally, in order to continue selling its products within the European
Economic Area and Switzerland following June 14, 1998, the Company will be
required to achieve compliance with the requirements of the Medical Devices
Directive ("MDD") and affix CE marking on its products to attest to such
compliance. The Company believes that products which have already been delivered
to distributors will be able to continue to be sold by such distributors during
a subsequent three-year transition period. To achieve compliance, the Company's
products must meet the "Essential Requirements" of the MDD relating to safety
and performance and the Company must successfully undergo verification of its
regulatory compliance ("conformity assessment") by a Notified Body selected by
the Company. The Company has selected TUV Product Service of Munich, Germany as
its Notified Body. The nature of such assessment depends on the regulatory class
of the product, and the many of the Company's coronary products are currently in
Class III, the highest risk class, and therefore subject to the most rigorous
controls.
In December 1996, the Company received ISO 9001/EN46001 certification from
its Notified body with respect to the manufacturing of all of its products. This
certification applies to the manufacturing operations in the Company's
24.
26
Irvine facilities and its contracted manufacturing facility in Nieuwegein,
Netherlands. In January 1998, the Company obtained the right to affix CE marking
to all of its products currently sold in all countries of the European Economic
Area and Switzerland. The Company will be subject to continued supervision by
its Notified Body and will be required to report any serious adverse incidents
to the appropriate authorities. The Company also will be required to comply with
additional national requirements that are beyond the scope of the MDD. With
respect to products not already cleared for CE marking, the Company will need to
comply with the CE marking requirements prior to June 14, 1998, or else it will
be unable to sell such additional products in the European Economic Area or
Switzerland unless and until compliance is achieved. Failure to achieve such
compliance could have a material adverse effect upon the Company's business,
financial condition and results of operations. There can be no assurance that
the Company will be able to achieve or maintain compliance required for CE
marking on all or any of its products or that it will be able to timely and
profitably produce its products while complying with the requirements of the MDD
and other regulatory requirements.
Limited Marketing and Sales Resources; Dependence Upon Strategic Partners. CVD
intends to rely primarily on certain strategic relationships, medical device
distributors and its direct sales organization to distribute its products, some
of which are competitors of the Company. See "Item 7. Risk Factors--Significant
Competitors. The Company's ability to distribute its products successfully
depends in part on the marketing capabilities of its strategic partners. In
recent years there has been significant consolidation among medical device
suppliers as the major suppliers have attempted to broaden their product lines
in order to respond to cost pressures from health care providers. This
consolidation has made it increasingly difficult for smaller suppliers, such as
the Company, to distribute their products effectively without a relationship
with one or more of the major suppliers. The Company is currently marketing
certain of its products through licensing agreements with SCIMED and ACS. In
addition, Cathex Co., Ltd. ("Cathex") is currently the Company's exclusive
distributor in Japan for certain products. Cathex is also responsible for
obtaining regulatory approval for the Company's products in Japan. The Company's
revenue from its distributor relationships is dependent upon the efforts made by
such parties and there can be no assurance that such efforts will be successful.
There can be no assurance that the Company will be able to maintain or expand
its relationships with its strategic partners or to replace its strategic
partners in the event any such relationship were terminated. In the event of
such a termination, the Company's ability to distribute its products would be
materially adversely affected, which would have a material adverse effect on the
Company's business, financial condition and results of operations.
CVD currently has a limited marketing and sales staff. The Company intends to
expand its direct sales force to market the Company's expanded product
offerings. However, there can be no assurance that CVD will successfully expand
its direct sales and marketing organization, or that if expanded, such
organization will be able to effectively distribute CVD's products. If CVD is
unable to achieve distribution of its products through its direct sales
organization, the Company's business, financial condition and results of
operations would be materially adversely affected.
The Company also has a product development relationship with SCIMED. In prior
years, SCIMED funded certain research and development efforts undertaken by CVD
in the area of combined drug delivery and coronary angioplasty. If CVD is unable
to obtain new relationships its product development efforts could be materially
adversely affected. Any disruption of the Company's product development efforts
would have a material adverse affect on the Company's business, financial
condition and results of operations. See "Item 1. Business--Marketing and Sales"
and "Item 1. Business--Strategic Relationships."
Dependence Upon International Sales. In 1997, 1996 and 1995, the Company's
international sales were $6.6 million, $3.5 million and 2.1 million,
respectively, or 58%, 42% and 59%, respectively, of product sales. The Company
expects to continue to derive significant revenue from international sales and
therefore a significant portion of the Company's revenues will continue to be
subject to the risks associated with international sales, including economic or
political instability, shipping delays, changes in applicable regulatory
policies, inadequate protection of intellectual property, fluctuations in
foreign currency exchange rates and various trade restrictions, all of which
could have a significant impact on the Company's ability to deliver products on
a competitive and timely basis. Future imposition of, or significant increases
in the level of, customs duties, import quotas or other trade restrictions,
could have an adverse effect on the Company's business, financial condition and
results of operation. In foreign countries, the Company's products are subject
to governmental review and certification. The regulation of medical devices,
particularly in the European Union, continues to expand and there can be no
assurance that new laws or regulations
25.
27
will not have an adverse effect on the Company's business, financial condition
and results of operations. See "Item 7. Management's Discussion and Analysis of
Financial Condition and Results of Operations."
Limitations on Third-Party Reimbursement. In the United States, the Company's
products are purchased primarily by medical institutions, which then bill
various third-party payors, such as Medicare, Medicaid, and other government
programs and private insurance plans, for the health care services provided to
patients. Government agencies, private insurers and other payors determine
whether to provide coverage for a particular procedure and reimburse hospitals
for medical treatment at a fixed rate based on the diagnosis-related group
("DRG") established by the U.S. Health Care Financing Administration ("HCFA").
The fixed rate of reimbursement is based on the procedure performed, and is
unrelated to the specific devices used in that procedure. If a procedure is not
covered by a DRG, payors may deny reimbursement. In addition, some payors may
deny reimbursement if they determine that the device used in a treatment was
unnecessary, inappropriate or not cost-effective, experimental or used for a
non-approved indication. Reimbursement of interventional procedures utilizing
the Company's products is currently covered under a DRG. There can be no
assurance that reimbursement for such procedures will continue to be available,
or that future reimbursement policies of payors will not adversely affect the
Company's ability to sell its products on a profitable basis. In addition,
reimbursement may be denied if the product use is not in accordance with
approved FDA labeling. Failure by hospitals and other users of the Company's
products to obtain reimbursement from third-party payors, or changes in
government and private third-party payors' policies toward reimbursement for
procedures employing the Company's products, would have a material adverse
effect on the Company's business, financial condition and results of operations.
See "Item 1. Business--Third-Party Reimbursement."
Control by Existing Stockholder; Limitations on Pooling-of-Interests Accounting
in Merger Transactions. EndoSonics owns approximately 20% of the Company's
outstanding voting Common Stock. As a result of the cumulative voting provision
in the Company's Amended and Restated Certificate of Incorporation, EndoSonics
is virtually assured of electing at least one member to the Company's five
person board of directors. The Company has proposed an amendment to the Amended
and Restated Certificate of Incorporation to eliminate cumulative voting of
directors which will be voted on at the 1998 Annual Meeting of Stockholders.
However, even in the event of approval of the amendment, Endosonics, as the
Company's largest single stockholder, will be able to exert significant
influence over the Company's affairs and the conduct of its business. Such
concentration of ownership may have the effect of delaying, deferring or
preventing a change in control of the Company. In accordance with applicable
accounting standards, the Company is prohibited from accounting for a merger
transaction, of or by the Company, as a pooling-of-interests for a period of two
years following June 25, 1996, the date on which EndoSonics ceased to control
50% of the outstanding voting Common Stock of the Company. As a result, any
business combination consummated prior to the expiration of such period would
have to be accounted for using the purchase method. Under the purchase method,
the excess of the purchase price over the net book value of the assets acquired
would be amortized as an expense, which could result in a significant negative
impact on the acquirer's results of operations and, therefore, reduce the
attractiveness of, or the price paid in, a particular acquisition transaction.
On January 27, 1997, EndoSonics announced that in connection with the
acquisition of Cardiometrics, Inc. ("Cardiometrics") by EndoSonics pursuant to
an Agreement and Plan of Reorganization, dated as of January 26, 1997, among
EndoSonics, River Acquisition Corporation, a wholly-owned subsidiary of
EndoSonics, and Cardiometrics, shares of the Company's Common Stock held by
EndoSonics would be distributed to the former stockholders, warrantholders and
optionholders of Cardiometrics. This acquisition was completed on July 23, 1997,
and EndoSonics distributed a total of 1,060,630 shares of CVD Common Stock.
After such distribution, EndoSonics owned approximately 33% of the Company's
outstanding Common Stock. On September 26, 1997, EndoSonics made a dividend
distribution of one CVD share for every 25 EndoSonics shares to its stockholders
and option holders of record on September 5, 1997. The distribution totaled
707,054 shares of CVD Common Stock, and reduced EndoSonics' ownership to
approximately 2,210,000 shares or 25% of the Company's Common Stock outstanding.
In February 1998, the Company purchased 300,000 shares of its Common Stock from
EndoSonics, thereby reducing their ownership to approximately 20% of the voting
Common Stock outstanding.
Potential Product Liability; Limited Insurance. The Company faces the risk of
financial exposure to product liability claims. The Company's products are often
used in situations in which there is a high risk of serious injury or death.
Such risks will exist even with respect to those products that have received, or
in the future may receive, regulatory approval for commercial sale. The Company
is currently covered under a product liability insurance policy with
26.
28
coverage limits of $2.0 million per occurrence and $2.0 million per year in the
aggregate. There can be no assurance that the Company's product liability
insurance is adequate or that such insurance coverage will remain available at
acceptable costs. There can be no assurance that the Company will not incur
significant product liability claims in the future. A successful claim brought
against the Company in excess of its insurance coverage could have a material
adverse effect on the Company's business, financial condition and results of
operations. Additionally, adverse product liability actions could negatively
affect the reputation and sales of the Company's products and the Company's
ability to obtain and maintain regulatory approval for its products and
substantially divert the time and effort of management away from the Company's
operations.
Volatility of Stock Price. Since the Company's initial public offering in June
1996, the price of the Company's Common Stock has fluctuated significantly. The
Company believes that factors such as variations in quarterly results of
operations, any future litigation involving the Company, announcements of
technological innovations or new products by the Company or its competitors,
governmental regulatory action, other developments or disputes with respect to
proprietary rights, general trends in the industry and overall market
conditions, and other factors, could cause the price of the Company's Common
Stock to fluctuate, perhaps substantially. In addition, in recent years the
stock market in general, and the market for small capitalization stocks in
particular, has experienced extreme price fluctuations which have often been
unrelated to the operating performance of affected companies. Such fluctuations
could adversely affect the market price of the Company's Common Stock.
Effect of Certain Charter Provisions; Anti-takeover Effects of Certificate of
Incorporation, Bylaws and Delaware Law. The Company's Board of Directors has the
authority to issue up to 5,000,000 shares of Preferred Stock and to determine
the price, rights, preferences, privileges and restrictions, including voting
rights, of those shares without any further vote or action by the stockholders.
The rights of the holders of Common Stock will be subject to, and may be
adversely affected by, the rights of the holders of any Preferred Stock that may
be issued in the future. The issuance of Preferred Stock could have the effect
of making it more difficult for a third party to acquire a majority of the
outstanding voting stock of the Company. In addition, the Company is subject to
the anti-takeover provisions of Section 203 of the Delaware General Corporation
Law, which will prohibit the Company from engaging in a "business combination"
with an "interested stockholder" for a period of three years after the date of
the transaction in which the person became an interested stockholder, unless the
business combination is approved in a prescribed manner. The application of
Section 203 also could have the effect of delaying or preventing a change of
control of the Company. In addition, the Company has proposed two amendments to
its Amended and Restated Certificate of Incorporation which will be voted on at
the 1998 Annual Meeting of Stockholders. One proposal eliminates cumulative
voting of directors, while the other proposal divides the Board of Directors
into three classes for staggered terms of three years. Both amendments are
designed to protect stockholder interests in the event of hostile takeover
attempts against the Company. However, either one of both amendments may have
the effect of delaying, deterring, or preventing a change in control of the
Company, which could adversely affect the market price of the Company's Common
Stock. Further, certain provisions of the Company's Certificate of Incorporation
and Bylaws and of Delaware law could delay or make more difficult a merger,
tender offer or proxy contest involving the Company, which could adversely
affect the market price of the Company's Common Stock.
Impact of Year 2000. The Company's computer programs were written using two
digits rather than four to define the applicable year. As a result, those
computer programs have time-sensitive software that recognize a date using "00"
as the year 1900 rather than the year 2000. This could cause a system failure or
miscalculations causing disruptions of operations, including, among other
things, a temporary inability to process finance, sales and inventory
transactions or engage in similar normal business activities.
The Company has completed an assessment and will have to upgrade portions of its
software so that its computer systems will function properly with respect to
dates in the year 2000 and thereafter. The total Year 2000 project cost is
estimated at $5,000 since the upgrades will be to existing software, which will
be capitalized. To date, the Company has spent a minor amount, primarily for the
assessment of the Year 2000 issue and the development of a modification plan and
upgrade of software.
The project is estimated to be completed not later than December 31, 1998, which
is prior to any anticipated impact on its operating systems. The Company
believes that with upgrades of existing software, the year 2000 issue will not
create significant operational problems for its computer systems. However, if
such upgrades are not
27.
29
made, or are not completed timely, the Year 2000 Issue could have a material
impact on the operations of the Company.
The costs of the project and the date on which the Company believes it will
complete the Year 2000 modifications are based on management's best estimates,
which were derived utilizing numerous assumptions of future events, including
the continued availability of certain resource and other factors. However, there
can be no guarantee that these estimates will be achieved and actual results
could differ materially from those anticipated. Specific factors that might
cause such material differences include, but are not limited to, the
availability and cost of personnel trained in this area, the ability to locate
and correct all relevant computer codes, and similar uncertainties.
Absence of Dividends. The Company has never paid any cash dividends on the
Common Stock and does not anticipate paying any cash dividends on the Common
Stock in the foreseeable future.
28.
30
ITEM 8. FINANCIAL STATEMENTS
Page
----
Report of Ernst & Young LLP, Independent Auditors.............................. F-1
Financial Statements
Consolidated Balance Sheets............................................. F-2
Consolidated Statements of Operations................................... F-3
Consolidated Statement of Stockholders' Equity (Net Capital Deficiency). F-4
Consolidated Statements of Cash Flows................................... F-5
Notes to Consolidated Financial Statements.............................. F-6
The financial statement schedule listed under Part IV, Item 14, is filed
as part of this Form 10-K.
29.
31
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE.
Not applicable.
PART III
ITEM 10. DIRECTORS AND OFFICERS OF THE REGISTRANT.
The information required by this item is incorporated by reference from
the Company's Proxy Statement, to be mailed to shareholders for the Annual
Meeting to be held on or about May 19, 1998. The information concerning the
Company's executive officers required by this item is incorporated by reference
to the section of Part I hereof entitled "Executive Officers of the Registrant."
ITEM 11. EXECUTIVE COMPENSATION.
The information required by this item is incorporated by reference from
the Company's Proxy Statement, to be mailed to shareholders for the Annual
Meeting to be held on or about May 19, 1998.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT.
The information required by this item is incorporated by reference from
the Company's Proxy Statement, to be mailed to shareholders for the Annual
Meeting to be held on or about May 19, 1998.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS.
The information required by this item is incorporated by reference from
the Company's Proxy Statement, to be mailed to shareholders for the Annual
Meeting to be held on or about May 19, 1998.
30.
32
PART IV
ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES, AND REPORTS ON FORM 8-K.
(a) The following documents are filed as a part of this Annual Report on
Form 10-K:
1. Financial Statements.
Report of Ernst & Young LLP, Independent Auditors
Consolidated Balance Sheets - December 31, 1996 and 1997
Consolidated Statements of Operations
for the years ended December 31, 1995, 1996 and 1997
Consolidated Statements of Stockholders' Equity
for the years ended December 31, 1995, 1996 and 1997
Consolidated Statements of Cash Flows
for the years ended December 31, 1995, 1996 and 1997
Notes to Consolidated Financial Statements
for the years ended December 31, 1995, 1996 and 1997
2. Financial Statement Schedule.
II - Valuation and Qualifying Accounts
Schedules not listed above have been omitted because they are
not applicable or are not required to be set forth
herein as such information is included in the
Consolidated Financial Statements or the notes thereto.
3. Exhibits. Reference is made to Item 14(c) of this Annual
Report on Form 10-K.
(b) Reports on Form 8-K. No reports on Form 8-K were filed during the
last quarter of the fiscal year covered by this Annual Report on
Form 10-K.
(c) Exhibits.
2.1(3) Agreement and Plan of Reorganization dated as of June 9, 1993 among
EndoSonics Corporation ("EndoSonics"), EndoSonics Acquisition
Corporation and CardioVascular Dynamics, Inc. ("CVD").
2.2(3) First Amendment dated as of June 30, 1993 to the Agreement and Plan of
Reorganization among EndoSonics, EndoSonics Acquisition Corporation
and CVD.
2.3(5) Agreement and Plan of Reorganization by and among CardioVascular
Dynamics, Inc., IDI Acquisition Corporation and Intraluminal Devices,
Inc. ("IDI") dated as of October 2, 1996.
3.1(3) Certificate of Incorporation.
3.2(3) Amended Bylaws.
4.1(1) Specimen Certificate of Common Stock.
10.1(3) Form of Indemnification Agreement entered into between the
Registrant and its directors and officers.
10.2(3)** The Registrant's 1996 Stock Option Plan and forms of agreements
thereunder.
31.
33
10.3(3)** The Registrant's Employee Stock Purchase Plan and forms of agreement
thereunder.
10.4(3) Series A Supplemental Stock Purchase Agreement dated June 5, 1992, by
and between Endosonics and CVD.
10.5(3) Stock Purchase Option Agreement dated June 5, 1992, by and between
EndoSonics and CVD.
10.6(3)* Japanese Distribution Agreement dated May 28, 1993, as amended on
October 27, 1994 and July 17, 1995, (the "Japanese Distribution
Agreements") by and between CVD and Fukuda Denshi Co., Ltd.
("Fukuda")
10.7(3)* Stock Purchase and Technology License Agreement dated September 10,
1994, as amended on September 29, 1995, by and among EndoSonics, CVD
and SCIMED Life Systems, Inc. ("SCIMED").
10.8(3) Waiver and Grant of Warrant dated June 30, 1995 by and between
SCIMED, CVD and Endosonics.
10.9(3)* License Agreement dated January 15, 1995 by and between CVD and
Advanced CardioVascular Systems, Inc. ("ACS").
10.10(3)* License Agreement dated March 4, 1996 by and between CVD and ACS.
10.11(3) Series B Stock Purchase Agreement dated March 29, 1996 by and between
CVD and EndoSonics.
10.12(3) License Agreement dated December 22, 1995 by and between CVD and
EndoSonics.
10.13(1) Form of Stockholder Agreement with EndoSonics.
10.14(1) Form of Tax Allocation Agreement with EndoSonics.
10.15(3) Industrial Lease dated February 23, 1995 by and between the Irvine
Company and CVD.
10.16(1) Waiver and Grant of Warrant dated May 2, 1996 by and between SCIMED,
CVD and EndoSonics.
10.17(2) Amendment to Japanese Distribution Agreements dated May 13, 1996 by
and between CVD and Fukuda.
10.18(4)* Supply Agreement dated July 15, 1996 by and between CVD and
Medtronic, Inc.
10.19(4)* OEM Agreement dated July 15, 1996 by and between CVD and Medtronic,
Inc.
10.20(6) License Agreement dated May 16, 1997 by and between CVD and
Endosonics.
10.21(6) Registration Rights Agreement dated May 14, 1997 by and between CVD
and EndoSonics.
10.22(7)** 1997 Supplemental Stock Option Plan.
23.1 Consent of Ernst & Young LLP, Independent Auditors.
24.1 Power of Attorney. (Reference is made to page 34 of this Annual
Report on Form 10-K.)
27.1 Financial Data Schedule.
- ----------
* Confidential treatment requested.
** Indicates compensatory plan or arrangement.
(1) Previously filed as an exhibit to Amendment No. 2 to the Company's
Registration Statement on Form S-1 filed with the Securities and Exchange
Commission on June 10, 1996.
(2) Previously filed as an exhibit to Amendment No. 1 to the Company's
Registration Statement on Form S-1 filed with the Securities and Exchange
Commission on May 17, 1996.
(3) Previously filed as an exhibit to the Company's Registration Statement on
Form S-1 filed with the Securities and Exchange Commission on May 3, 1996.
(4) Previously filed as an exhibit to the Company's report on Form 10-Q filed
with the Securities and Exchange Commission on August 14, 1996.
(5) Previously filed as an exhibit to the Company's Registration Statement on
Form S-1 filed with the Securities and Exchange Commission on November 12,
1996.
(6) Previously filed as an exhibit to the Company's Registration Statement on
Form S-1 filed with the Securities and Exchange Commission on June 19,
1997.
(7) Previously filed as an exhibit to the Company's Registration Statement on
Form S-8 filed with the Securities and Exchange Commission on December 12,
1997.
32.
34
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
CARDIOVASCULAR DYNAMICS, INC.
Date: March 30, 1998 By: /s/ Michael R. Henson
-----------------------------------
Michael R. Henson
Chief Executive Officer
(Principal Executive Officer) and Chairman
Date: March 30, 1998 By: /s/ Dana P. Nickell
-----------------------------------
Dana P. Nickell
Vice President, Finance and Administration,
Chief Financial Officer and Secretary
(Principal Financial and Accounting Officer)
33.
35
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature
appears below constitutes and appoints, jointly and severally, Michael R. Henson
and Dana P. Nickell, and each of them, as his true and lawful attorneys-in-fact
and agents, with full power of substitution and resubstitution, for him and in
his name, place and stead, in any and all capacities, to sign any and all
amendments (including post-effective amendments) to this Report on Form 10-K,
and to file the same, with all exhibits thereto, and other documents in
connection therewith, with the Securities and Exchange Commission, granting unto
said attorneys-in-fact and agents, and each of them, full power and authority to
do and perform each and every act and thing requisite and necessary to be done
in connection therewith, as fully to all intents and purposes as he might or
could do in person, hereby ratifying and confirming all that said
attorneys-in-fact and agents, or any of them, or their or his substitute or
substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this
report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.
SIGNATURE TITLE DATE
--------- ----- ----
/s/ Michael R. Henson Chief Executive Officer March 30, 1998
- ----------------------------------- (Principal Executive
(Michael R. Henson) Officer) and Chairman
/s/ Dana P. Nickell Vice President, Finance and March 30, 1998
- ----------------------------------- Administration, Chief Financial
(Dana P. Nickell) Officer and Secretary (Principal
Financial and Accounting Officer)
/s/ Franklin D. Brown Director March 30, 1998
- -----------------------------------
(Franklin D. Brown)
/s/ William G. Davis Director March 30, 1998
- -----------------------------------
(William G. Davis)
/s/ Gerard von Hoffmann Director March 30, 1998
- -----------------------------------
(Gerard von Hoffmann)
/s/ Edward M. Leonard Director and Assistant Secretary March 30, 1998
- -----------------------------------
(Edward M. Leonard)
36
REPORT OF ERNST & YOUNG LLP, INDEPENDENT AUDITORS
The Board of Directors and Shareholders
CardioVascular Dynamics, Inc.
We have audited the accompanying consolidated balance sheets of
CardioVascular Dynamics, Inc. and subsidiaries as of December 31, 1996 and 1997,
and the related consolidated statements of operations, stockholders' equity (net
capital deficiency) and cash flows for each of the three years in the period
ended December 31, 1997. Our audits also included the financial statement
schedule listed in the Index at Item 14(a). These financial statements are the
responsibility of the Company's management. Our responsibility is to express an
opinion on these financial statements based on our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to above
present fairly, in all material respects, the consolidated financial position of
CardioVascular Dynamics, Inc. and subsidiaries at December 31, 1996 and 1997,
and the consolidated results of its operations and its cash flows for each of
the three years in the period ended December 31, 1997, in conformity with
generally accepted accounting principles. Also, in our opinion, the related
financial statement schedule, when considered in relation to the basic
consolidated financial statements taken as a whole, presents fairly in all
material respects the information set forth therein.
/s/ ERNST & YOUNG LLP
Orange County, California
January 29, 1998
F-1
37
CARDIOVASCULAR DYNAMICS, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share amounts)
December 31
--------------------------
1996 1997
---------- ----------
ASSETS
Current Assets:
Cash and cash equivalents ........................................... $ 17,192 $ 6,141
Marketable securities available-for-sale ............................ 25,733 24,773
Accounts receivable, net of allowance for doubtful accounts of $377
and $500, respectively ............................................ 2,268 2,752
Other accounts receivable ........................................... 320 282
Inventories ......................................................... 2,899 3,205
Other current assets ................................................ 162 163
---------- ----------
Total current assets .......................................... 48,574 37,316
Property and Equipment:
Furniture and equipment ............................................. 1,161 1,871
Leasehold improvements .............................................. 310 322
---------- ----------
1,471 2,193
Less accumulated depreciation and amortization ...................... (289) (643)
---------- ----------
Net property and equipment ........................................ 1,182 1,550
Goodwill, net of amortization of $78 ................................ -- 1,809
Notes receivable from officers ...................................... 325 273
Other assets ........................................................ 3 413
---------- ----------
Total assets ...................................................... $ 50,084 $ 41,361
========== ==========
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable and accrued expenses ............................... $ 2,382 $ 3,488
Deferred distributorship fee revenue, current portion ............... 50 --
---------- ----------
Total current liabilities ........................................... 2,432 3,488
Deferred distributorship fee revenue .................................... 29 --
Commitments (Note 10)
Stockholders' equity
Convertible Preferred Stock, $.001 par value; 7,560,000 shares
authorized, 2,000,000 and no shares issued and outstanding....... -- --
Common Stock, $.001 par value; 30,000,000 shares authorized,
9,004,000 and 9,389,000 shares issued and outstanding at December
31, 1996 and 1997, respectively ................................. 9 9
Additional paid-in capital .......................................... 58,869 60,371
Deferred compensation ............................................... (376) (634)
Accumulated deficit ................................................. (11,049) (19,821)
Treasury stock, at cost, 345,000 common shares ...................... -- (2,205)
Unrealized gain on available-for-sale securities .................... 170 176
Unrealized exchange rate loss ....................................... -- (23)
---------- ----------
Total stockholders' equity ...................................... 47,623 37,873
---------- ----------
Total liabilities and stockholders' equity ...................... $ 50,084 $ 41,361
========== ==========
See accompanying notes.
F-2
38
CARDIOVASCULAR DYNAMICS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
YEAR ENDED DECEMBER 31,
------------------------------------------
Revenue: 1995 1996 1997
---------- ---------- ----------
Sales .......................................................... $ 3,462 $ 8,384 $ 11,332
License fee and other from related party ....................... -- 150 --
Contract ....................................................... 641 200 --
---------- ---------- ----------
Total revenue ................................................ 4,103 8,734 11,332
Operating costs and expenses:
Cost of sales .................................................. 2,051 4,111 6,418
Charge for acquired in-process research and development ........ 488 2,133 --
Research and development ....................................... 1,683 3,582 7,041
Marketing and sales ............................................ 1,526 3,358 6,691
General and administrative (including $340 and $156 for the years
ended December 31, 1995 and 1996, respectively, paid to
EndoSonics) ............................................... 1,331 1,548 2,179
---------- ---------- ----------
Total operating costs and expenses ........................... 7,079 14,732 22,329
---------- ---------- ----------
Loss from operations ............................................ (2,976) (5,998) (10,997)
Other Income:
Interest income ................................................. 42 1,324 2,201
Distributorship fees and other income ........................... 60 50 24
---------- ---------- ----------
Total other income ........................................... 102 1,374 2,225
---------- ---------- ----------
Net Loss ........................................................ $ (2,874) $ (4,624) $ (8,772)
========== ========== ==========
Basic and diluted net loss per share (pro forma through
June 1996) ................................................... $ (0.71) $ (0.69) $ (0.96)
========== ========== ==========
Shares used in computing basic and diluted net loss per share
(pro forma through June 1996) ................................ 4,052 6,755 9,118
========== ========== ==========
See accompanying notes.
F-3
39
CARDIOVASCULAR DYNAMICS, INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (NET CAPITAL DEFICIENCY)
(In thousands, except share amounts)
Preferred Stock Common Stock Additional
------------------------ ------------------------ Paid-In Deferred
Shares Amount Shares Amount Capital Compensation
---------- ---------- ---------- ---------- ---------- ------------
Balance at December 31, 1994 .......... -- $ -- 4,000,000 $ 4 $ 4,835 --
Additional effects of merger with
EndoSonics Acquisition Corp. ... -- -- -- -- 488 --
Issuance of Preferred Stock in
Exchange for Common Stock ...... 2,000,000 2 (4,000,000) (4) 2 --
Deferred compensation resulting
From grant of options .......... -- -- -- -- 345 (345)
Net Loss .............................. -- -- -- -- -- --
---------- ---------- ---------- ---------- ---------- ----------
Balance at December 31, 1995 .......... 2,000,000 2 -- -- 5,670 (345)
Sale of Preferred Stock to EndoSonics . 400,000 -- -- -- 8,000 --
Conversion of Preferred Stock ......... (2,400,000) (2) 4,800,000 5 (3) --
Exercise of Common Stock Options ...... -- -- 139,000 -- 138 --
Initial Public Offering of
Common Stock ................... -- -- 3,910,000 4 42,764 --
Deferred compensation resulting
From grant of options .......... -- -- -- -- 150 (150)
Amortization of deferred
Compensation ................... -- -- -- -- -- 119
Acquisition of Intraluminal
Devices, Inc. .................. -- -- 93,000 -- 1,400 --
Conversion of $750,000 debit by
Fukuda Denshi .................. -- -- 62,000 -- 750 --
Net loss ............................. -- -- -- -- -- --
Unrealized gain on investments ........ -- -- -- -- -- --
---------- ---------- ---------- ---------- ---------- ----------
Balance of December 31, 1996 .......... -- -- 9,004,000 9 58,869 (376)
Exercise of common stock options ...... -- -- 208,000 -- 238 --
Employee stock purchase plan .......... -- -- 33,000 -- 266 --
SCIMED warrant exercise ............... -- -- 120,000 -- 377 --
Sale of common stock to Cathex ........ -- -- 25,000 -- 200 --
Expense repayment by Intraluminal
Devices, Inc. by transfer and
cancellation of common stock ... -- -- (1,000) -- (16) --
Deferred compensation resulting from
grant of options ............... -- -- -- -- 437 (437)
Amortization of deferred
compensation ................... -- -- -- -- -- 179
Treasury Common Stock ................. -- -- -- -- -- --
Net Loss .............................. -- -- -- -- -- --
Unrealized gain on investments ........ -- -- -- -- -- --
Unrealized exchange rate loss ......... -- -- -- -- -- --
---------- ---------- ---------- ---------- ---------- ----------
Balance at December 31, 1997 .......... -- $ -- 9,389,000 $ 9 $ 60,371 $ (634)
========== ========== ========== ========== ========== ==========
Total
Stockholders'
Treasury Unrealized Unrealized Equity
Accumulated ----------------------- Gain on Exchange (Net Capital
Deficit Shares Amount Investments Rate Loss Deficiency)
----------- ---------- ---------- ----------- ---------- ----------
Balance at December 31, 1994 .......... $ (3,551) -- $ -- $ -- $ -- $ 1,288
Additional effects of merger with
EndoSonics Acquisition Corp. ... -- -- -- -- -- 488
Issuance of Preferred Stock in
Exchange for Common Stock ...... -- -- -- -- -- --
Deferred compensation resulting
From grant of options .......... -- -- -- -- -- --
Net Loss .............................. (2,874) -- -- -- -- (2,874)
---------- ---------- ---------- ---------- ---------- ----------
Balance at December 31, 1995 .......... (6,425) -- -- -- -- (1,098)
Sale of Preferred Stock to EndoSonics . -- -- -- -- -- 8,000
Conversion of Preferred Stock ......... -- -- -- -- -- --
Exercise of Common Stock Options ...... -- -- -- -- -- 138
Initial Public Offering of
Common Stock ................... -- -- -- -- -- 42,768
Deferred compensation resulting
From grant of options .......... -- -- -- -- -- --
Amortization of deferred
Compensation ................... -- -- -- -- -- 119
Acquisition of Intraluminal
Devices, Inc. .................. -- -- -- -- -- 1,400
Conversion of $750,000 debit by
Fukuda Denshi .................. -- -- -- -- -- 750
Net loss ............................. (4,624) -- -- -- -- (4,624)
Unrealized gain on investments ........ -- -- -- 170 -- 170
---------- ---------- ---------- ---------- ---------- ----------
Balance of December 31, 1996 .......... (11,049) -- -- 170 -- 47,623
Exercise of common stock options ...... -- -- -- -- -- 238
Employee stock purchase plan .......... -- -- -- -- -- 266
SCIMED warrant exercise ............... -- -- -- -- -- 377
Sale of common stock to Cathex ........ -- -- -- -- -- 200
Expense repayment by Intraluminal
Devices, Inc. by transfer and
cancellation of common stock ... -- -- -- -- -- (16)
Deferred compensation resulting from
grant of options ............... -- -- -- -- -- --
Amortization of deferred
compensation ................... -- -- -- -- -- 179
Treasury Common Stock ................. -- 345 (2,205) -- -- (2,205)
Net Loss .............................. (8,772) -- -- -- -- (8,772)
Unrealized gain on investments ........ -- -- -- 6 -- 6
Unrealized exchange rate loss ......... -- -- -- -- (23) (23)
---------- ---------- ---------- ---------- ---------- ----------
Balance at December 31, 1997 .......... $ (19,821) $ 345 $ (2,205) $ 176 $ (23) $ (37,873)
========== ========== ========== ========== ========== ==========
See accompanying notes
F-4
40
CARDIOVASCULAR DYNAMICS, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
YEAR END DECEMBER 31,
-----------------------------------
1995 1996 1997
-------- --------- --------
Operating activities
Net loss ......................................................... $(2,874) $ (4,624) $ (8,772)
Adjustments to reconcile net loss to net cash used in operating
activities:
Depreciation and amortization ................................... 74 182 432
Amortization of deferred compensation ........................... -- 119 179
Bad debt expense ................................................ 249 221 318
Charge for acquired in-process research and development ......... 488 1,400 --
Net changes in:
Trade accounts receivable, net .................................. (639) (1,372) (2,767)
Receivable from related parties ................................. 125 -- --
Inventories ..................................................... (704) (2,145) 10
Other assets .................................................... (135) (671) 37
Accounts payable and accrued expenses ........................... 1,369 698 836
Deferred distributor fee revenue ................................ (54) (50) (79)
------- -------- --------
Net cash used in operating activities .............................. (2,101) (6,242) (9,806)
Investing activities:
Purchase of available-for-sale securities ........................ -- (25,563) (43,208)
Sales of available-for-sale securities ........................... -- -- 44,174
Capital expenditures for furniture, fixtures and equipment ....... (443) (940) (699)
Purchase of Clintec, net of cash acquired ........................ -- -- (30)
Change in other assets ........................................... -- -- (358)
------- -------- --------
Net cash used in investing activities .............................. (443) (26,503) (121)
--------
Financing activities:
Proceeds from issuance of convertible obligation ................. 750 -- --
Proceeds from sale of Common Stock ............................... -- 42,768 466
Proceeds from exercise of stock warrants ......................... -- -- 377
Proceeds from exercise of stock options .......................... -- 138 238
Proceeds from sale of Preferred Stock to EndoSonics .............. -- 8,000 --
Purchase of treasury common stock ................................ -- -- (2,205)
Payable to EndoSonics, net ....................................... (17) (2,537) --
------- -------- --------
Net cash provided by (used in) financing activities ................ 733 48,369 (1,124)
------- -------- --------
Net increase (decrease) in cash .................................... (1,811) 15,624 (11,051)
Cash and cash equivalents, beginning of period ..................... 3,379 1,568 17,192
------- -------- --------
Cash and cash equivalents, end of period ........................... $ 1,568 $ 17,192 $ 6,141
======= ======== ========
Supplemental disclosure of non-cash financing activities:
Common stock issued upon the acquisition of Intraluminal
Devices, Inc., Note 1 ........................................... $ -- $ 1,400 $ --
Conversion of Debentures to Common Stock, Note 5 ................... -- 750 --
See accompanying notes.
F-5
41
CARDIOVASCULAR DYNAMICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share amounts)
1. BUSINESS, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES
Business and Basis of Presentation
CardioVascular Dynamics, Inc. (the "Predecessor") was incorporated on
March 16, 1992 in the State of California. The Predecessor, and its successor
corporation discussed below, develops, manufactures and markets proprietary
therapeutic catheters used to treat certain vascular diseases.
In June 1992, EndoSonics Corporation ("EndoSonics") acquired a 40% preferred
interest in the Predecessor. EndoSonics, a Delaware corporation, develops,
manufactures, and markets intravascular ultrasound imaging systems and
diagnostic, therapeutic and imaging catheters for the treatment of coronary and
peripheral vascular disease.
In June 1993, EndoSonics acquired all of the remaining Preferred and Common
Stock of the Predecessor. The acquisition was accomplished through a merger
between the Predecessor and EndoSonics Acquisition Corp., a wholly owned
subsidiary of EndoSonics (which then changed its name to CardioVascular
Dynamics, Inc.) (hereinafter referred to as "CVD" or the "Company").
The acquisition by EndoSonics resulted in a new basis for the CVD assets and
liabilities. Accordingly, the purchase price paid by EndoSonics has been
allocated to the identifiable assets and liabilities, including in-process
research and development, which was immediately expensed as no CVD products had
received regulatory approval and the technology did not have identifiable
alternative uses. The amount by which the purchase price exceeded the
Predecessor's net book value has been reflected as paid-in capital in the
accompanying financial statements. Pursuant to the terms of the original merger
agreement, in June 1995 EndoSonics issued an additional 50,000 shares of its
Common Stock to the former shareholders of the Predecessor. The fair market
value of such shares of $488 has been reflected in the accompanying financial
statements as an additional charge for acquired in-process technology.
Subsequent to the acquisition, EndoSonics began performing certain services for
CVD (see Note 4), including general management, accounting, cash management, and
other administrative and engineering services. The amounts charged to CVD for
such services have been determined based on proportional cost allocations and
have been agreed to by the management of CVD and EndoSonics. In the opinion of
CVD's management, the allocation methods used are reasonable. Such allocations,
however, are not necessarily indicative of costs that would have been incurred
had CVD continued to operate independent of EndoSonics. No formal agreement
currently exists which specifies the nature of services to be provided by
EndoSonics to CVD, or the charges for such services. Therefore, amounts are not
necessarily indicative of the future charges to be incurred by CVD.
In 1994 and 1996, the Board of Directors of CVD approved a 16,200-for-1 and a
2-for-1 Common Stock split, respectively, which has been reflected retroactively
for all periods in the accompanying financial statements.
On June 25, 1996, the Company closed its initial public offering (the
"Offering") which consisted of 3,400,000 shares of Common Stock at $12.00 per
share. On July 17, 1996, the Company's underwriters exercised their
overallotment option to purchase an additional 510,000 shares of Common Stock at
$12.00 per share. CVD received net offering proceeds from the sale of Common
Stock of approximately $42.8 million after deducting underwriting discounts and
commissions and other expenses of the Offering.
F-6
42
CARDIOVASCULAR DYNAMICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)
In October 1996, CVD acquired 100% of the common stock of Intraluminal Device,
Inc. ("IDI") in exchange for CVD common stock valued at $1.4 million. The
acquisition was accomplished through the formation of IDI Acquisition, Inc., a
wholly-owned subsidiary of CVD, and the merging of IDI into IDI Acquisition,
Inc. (See Note 2).
In July 1997, CVD the Company acquired all of the common stock of Clinitec GmbH
("Clinitec") its independent distributor in Germany and Switzerland, in exchange
for the assumption of the assets and liabilities of Clinitec.
The consolidated financial statements for December 31, 1996 and 1997 include the
accounts of the Company and its subsidiaries. Intercompany transactions have
been eliminated.
Use of Estimates
The preparation of financial statements in conformity with generally accepted
accounting principles requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities at the date of the
financial statements and the reported amounts of revenues and expenses during
the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents
Cash and cash equivalents includes cash on hand, demand deposits, and short-term
investments with original maturities of three months or less.
Marketable Securities Available-For-Sale
The Company accounts for its investments pursuant to Statement of Financial
Accounting Standards No. 115, "Accounting for Certain Investments in Debt and
Equity Securities" ("SFAS 115").
The Company has classified its entire investment portfolio as
available-for-sale. Available-for-sale securities are stated at fair value with
unrealized gains and losses included in shareholders' equity. The amortized cost
of debt securities is adjusted for amortization of premiums and accretions of
discounts to maturity. Such amortization is included in interest income.
Realized gains and losses are included in other income (expense). The cost of
securities sold is based on the specific identification method.
Inventories
Inventories are comprised of raw materials, work-in-process and finished goods
and are stated at the lower of cost, determined on an average cost basis, or
market value.
Property and Equipment
Property and equipment are stated at cost and depreciated or amortized on a
straight-line basis over the lesser of the estimated useful lives of the assets
or the lease term. The estimated useful lives range from three to seven years.
F-7
43
CARDIOVASCULAR DYNAMICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)
Goodwill
The excess of the purchase price over the net assets of the business acquired
("goodwill") is amortized on the straight-line method over the estimated
recovery period. The goodwill stemming from the purchase of Clinitec is
amortized over ten years (See Note 2).
The carrying value of goodwill is reviewed if the facts and circumstances
suggest that it may be impaired. If this review indicates that goodwill will
not be recoverable, as determined based on the undiscounted cash flows of the
entity acquired over the remaining amortization period, the carrying value of
the goodwill is reduced to estimated fair value.
Long-lived Assets
The Company records impairment losses on long-lived assets used in operations
when events and circumstances indicate that the assets might be impaired and
the undiscounted cash flows estimated to be generated by those assets are less
than the carrying amounts of those assets.
Concentrations of Credit Risk and Significant Customers
The Company maintains its cash and cash equivalents in deposit accounts and in
pooled investment accounts administered by a major financial institution.
The Company sells its products primarily to medical institutions and
distributors worldwide. The Company performs ongoing credit evaluations of its
customers' financial condition and generally does not require collateral from
customers. Management believes that an adequate allowance for doubtful accounts
has been provided.
During 1995, 1996 and 1997 product sales to Fukuda Denshi Co., Ltd., ("Fukuda"),
the Company's Japanese distributor (see Note 5), comprised 18%, 14% and 7% of
total revenue, respectively. Accounts receivable from Fukuda represented 1% and
0% of net accounts receivable at December 31, 1996 and 1997, respectively.
The Company terminated its Agreement with Fukuda in May 1997 and signed a
five-year agreement with another Japan distributor, Cathex, LTD. ("Cathex").
During 1997, Product sales to Cathex comprised 13% of total revenues. Accounts
receivable from Cathex represented 44% of net accounts receivable at December
31, 1997.
Product sales to Medtronic, Inc. ("Medtronic") accounted for 21% and 13% of
total revenues during 1996 and 1997, respectively. At December 31, 1996 and
1997, 27% and 0%, respectively, of net accounts receivable were due from
Medtronic. In May of 1997, Medtronic advised the Company of its election to not
make minimum purchases of product for the second year of the agreement. In June
1997, Medtronic informed CVD it would not fulfill its commitment for the first
year of the agreement and it did not believe it was required to fulfill such
commitment.
One other customer comprised 12% of revenues for the year ended December 31,
1995 and 14% of accounts receivable at December 31, 1995.
F-8
44
CARDIOVASCULAR DYNAMICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)
Export Sales
The Company had export sales by region as follows:
Year Ended
December 31,
----------------------------------
1995 1996 1997
-------- -------- --------
Europe ... $ 1,179 $ 1,614 $ 3,020
Japan .... 744 1,240 2,350
Latin
America.. 131 243 253
Other .... -- 417 956
-------- -------- --------
$ 2,054 $ 3,514 $ 6,579
======== ======== ========
Revenue Recognition and Warranty
The Company recognizes revenue from the sale of its products when the goods are
shipped to its customers. Reserves are provided for anticipated product returns
and warranty expenses at the time of shipment. License fees are recognized on a
contract with SCIMED Life Systems, Inc. ("SCIMED") when distribution rights to
certain markets are made available to SCIMED for the sale of products based upon
certain limited catheter technology. Contract revenues are recognized on
contracts with SCIMED and Advanced CardioVascular Systems, Inc. ("ACS") for
transferring certain limited catheter technology based upon the Company's
completion of (1) technical Assistance to aid SCIMED in manufacturing the
related products, and (2) research and development to develop the related
products for ACS and SCIMED (See Note 3).
Accounting for Stock-Based Compensation
The Company has elected to follow Accounting Principles Board Opinion No. 25,
"Accounting for Stock Issued to Employees" (APB 25) and related Interpretations
in accounting for its employee stock options because, as discussed below, the
alternative fair value accounting provided for under FASB Statement No. 123,
"Accounting for Stock-Based Compensation," requires use of option valuation
models that were not developed for use in valuing employee stock options. Under
APB 25, because the exercise price of the Company's employee stock options
equals the market price of the underlying stock on the date of grant, no
compensation expense is recognized.
Pro forma information regarding net income and earnings per share is required by
Statement 123, which also requires that the information be determined as if the
Company has accounted for its employee stock options granted subsequent to
December 31, 1994 under the fair value method of that Statement. The fair value
for these options was estimated at the date of grant using the Black-Scholes
option pricing model. The Black-Scholes model was developed for use in
estimating the fair value of traded options which have no vesting restrictions
and are fully transferable. In addition, option valuation models require the
input of highly subjective assumptions including the expected stock price
volatility. Because the Company's employee stock options have characteristics
significantly different from those of traded options, and because changes in the
subjective input assumptions can materially affect the fair value estimate, in
management's opinion, the existing models do not necessarily provide a reliable
single measure of the fair value of its employee stock options.
F-9
45
CARDIOVASCULAR DYNAMICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)
In calculating pro forma information regarding net income and net income per
share the fair value was estimated at the date of grant using a Black-Scholes
option pricing model with the following weighted-average assumptions for the
options on the Company's common stock: risk-free interest rate of 6.0 %, 6.0%
and 5.5%; a dividend yield of 0%, 0% and 0%; volatility of the expected market
price of the Company's common stock of 0.475, 0.475 and 0.692; and a
weighted-average expected life of the options of 3.5, 3.5 and 5.0 years for
1995, 1996 and 1997, respectively.
For purposes of pro forma disclosures, the estimated fair value of the options
is amortized to expense over the options' vesting period. The Company's pro
forma information for the years ended December 31, 1995, 1996 and 1997 follows:
1995 1996 1997
------------ ------------ ------------
Pro forma net loss ............. $ (2,905) $ (5,170) $ (9,320)
Pro forma basic and diluted
net loss per share ........... $ (0.72) $ (0.77) $ (1.02)
Because Statement 123 is applicable only to options granted subsequent to
December 31, 1994, its pro forma effect will not be fully reflected until 1997.
Recent Accounting Pronouncements
In June 1997, the Financial Accounting Standards Board issued Statement of
Financial Accounting Standards No. 130, Reporting Comprehensive Income
(Statement No. 130), which is effective for years beginning after December 15,
1997. Statement No. 130 establishes standards for reporting and displaying
comprehensive income and its components with the same prominence as other
financial statement information. Management has not completed its review of
Statement No. 130, but does not anticipate that the adoption of this statement,
other than required financial statement reclassifications, will have a
significant effect on the Company's reported financial position.
In June 1997, the Financial Accounting Standards Board issued Statement of
Financial Accounting Standards No. 131, Disclosures about Segments of an
Enterprise and Related Information (Statement No. 131), which is effective for
years beginning after December 15, 1997. Statement No. 131 establishes
standards for the way that public business enterprises report information about
operating segments in annual financial statements and requires that those
enterprises report selected information about operating segments in interim
financial reports. It also establishes standards for related disclosures about
products and services, geographic areas, and major customers. Statement No. 131
is effective for financial statements for fiscal years beginning after December
15, 1997, and therefore the Company will adopt the new requirements
retroactively in 1998. The Company operates in one business segment.
Accordingly, the Company does not anticipate that the adoption of this
statement will have a significant effect on the Company's financial statements.
In March 1998, the AICPA issued SOP 98-1, Accounting for the Costs of Computer
Software Developed For or Obtained For Internal Use. The SOP is effective for
companies beginning on January 1, 1999. The SOP will require the capitalization
of certain costs incurred after the date of adoption in connection with
developing or obtaining software for internal use. The Company currently
expenses such costs. The Company has not yet assessed what the impact of the SOP
will be on the Company's future earnings or financial position.
Income Taxes
From June 1993 until June 1996, the Company's results of operations have been
included in consolidated tax returns filed by EndoSonics. There was no income
tax provision for the consolidated tax group during the periods covered by these
financial statements. All net operating loss and credit carryforwards and
deferred tax assets and liabilities have been disclosed herein on a separate
company basis for CVD.
Net Loss Per Share
In 1997, the Financial Accounting Standards Board issued Statement No. 128,
Earnings per Share. Statement No. 128 replaced the calculation of primary and
fully diluted earnings per share with basic and diluted earnings per share.
Unlike primary earnings per share, basic earnings per share excludes any
dilutive effects of options, warrants and convertible securities. Diluted
earnings per share is very similar to the previously reported fully diluted
earnings per share. All earnings per share amounts for all periods have been
presented to conform with Statement No. 128.
Net loss per common share after the Company's initial public offering is
computed using the weighted average number of common shares outstanding during
the periods presented. Options to purchase shares of the Company's common stock
granted under the Company's stock option plan may have a dilutive effect on the
Company's earnings per share in the future. Net loss per share prior to the
Company's initial public offering is computed on a pro forma basis using the
weighted average number of shares of Common Stock, convertible Preferred Stock
(using the as-if-converted method) and Common Stock issuable upon conversion of
the Convertible Obligation, outstanding. The following table sets forth the
computation of basic and diluted net loss per share:
F-10
46
CARDIOVASCULAR DYNAMICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)
YEARS ENDED DECEMBER 31,
---------------------------------------
1995 1996 1997
--------- --------- ---------
(In thousands)
NUMERATOR:
Net loss .............................................. $ (2,874) $ (4,624) $ (8,772)
--------- --------- ---------
Net loss used for basic and diluted loss per share--
loss attributable to common stockholders ............ $ (2,874) $ (4,624) $ (8,772)
========= ========= =========
DENOMINATOR:
Denominator for basic and diluted loss per share--
weighted average common shares outstanding .......... 385 4,715 9,118
Assumed conversion of Preferred Stock from the date
of issuance (Series A and B)......................... 3,667 2,040 --
--------- --------- ---------
4,052 6,755 9,118
========= ========= =========
Basic and diluted net loss per share .................. $ (0.71) $ (0.69) $ (0.96)
========= ========= =========
2. ACQUISITIONS
On October 16, 1996, the Company acquired all of the outstanding shares of
Intraluminal Devices, Inc. ("IDI") in exchange for approximately 93,000 shares
of CVD common stock valued at $1.4 million. The acquisition was accounted for
using the purchase method of accounting. As the assets of IDI were patents for
products still in their development stage, the purchase price and the associated
costs of acquisition $0.7 million were expensed as acquired in-process research
and development.
On July 29, 1997, the Company acquired all of the common stock of its
independent distributor in Germany and Switzerland, Clinitec GmbH ("Clinitec").
The aggregate purchase price of the acquisition was $1,636 and consisted of cash
of $30 and the forgiveness of debt of $1,606. The transaction was accounted for
by the purchase method of accounting and, accordingly, the purchase price was
allocated to the assets acquired and the liabilities assumed based on their fair
market values at the date of acquisition. In connection with the acquisition,
the Company acquired assets and assumed liabilities with fair market values of
$401 and $652, respectively. The excess of the purchase price over the fair
value of the net assets acquired of $1,887 has been allocated to goodwill. The
results of operations of Clinitec are included in the consolidated statement of
operations subsequent to the date of acquisition.
The following table reflects unaudited pro forma combined results of operations
of the Company, IDI and Clinitec on the basis that the acquisitions had taken
place and the related charge for IDI, noted above, was recorded at the beginning
of 1996 for IDI and Clinitec, as IDI operations were not material to the
Company's operations prior to 1996:
1996 1997
------- -------
Revenues......................... $8,822 $11,633
Net Loss......................... (5,060) (9,484)
Net Loss per common share........ (0.75) (1.04)
Shares used in computation....... 6,755 9,118
F-11
47
CARDIOVASCULAR DYNAMICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)
In management's opinion, the unaudited pro forma combined results of operations
are not indicative of the actual results that would have occurred had the
acquisitions been consummated at the beginning of 1996 or 1997, respectively, or
of future operations of the combined companies under the ownership and
management of the Company.
3. SCIMED LIFE SYSTEMS, INC.
In September 1994, CVD and EndoSonics entered into a Stock Purchase and
Technology License Agreement with SCIMED Life Systems, Inc. ("SCIMED"). SCIMED
acquired a 19% interest in CVD in exchange for $2,500 in cash.
CVD also granted SCIMED an exclusive license to certain patents in the
cardiovascular field of use, which allows SCIMED to manufacture the Transport
PTCA infusion catheter (the "Transport") developed by CVD in exchange for a
$1,000 license fee that was paid in 1994. SCIMED will pay royalties to CVD on
sales of the Transport and other products which use this patented technology.
CVD retains rights to this technology and the associated patents for use outside
of the cardiovascular field.
During June 1995, the Company issued a warrant to SCIMED to purchase up to
80,000 shares of Series A Preferred Stock at an exercise price of $3.29 per
share in exchange for a waiver of SCIMED's anti-dilution right.
During May 1996, the Company issued an additional warrant to SCIMED to
purchase up to 40,000 shares of Series A Preferred Stock at an exercise price of
$3.29 per share in exchange for a waiver of SCIMED's anti-dilution right related
to the shares to be issued under the 1996 Plan. In August 1997, SCIMED exercised
all 120,000 warrants, mentioned above.
SCIMED also paid CVD $641, $200 and $0 in 1995, 1996 and 1997, respectively, on
a cost reimbursement basis to fund continuing development of the technology and
for other support.
4. RELATED PARTY TRANSACTIONS
The following is a summary of significant transactions between CVD and
EndoSonics:
During a portion of 1995, EndoSonics manufactured certain of the Company's
catheter products at cost plus a mark-up of 30%. Total purchases from
EndoSonics during 1995 amount to $172.
Prior to the Company's initial public offering in June 1996, certain
EndoSonics corporate expenses, primarily related to executive management
time, accounting, cash management, and other administrative and
engineering services, have been allocated to the Company. Total expenses
allocated were $340 and $156 for the years ended December 31, 1995 and
1996, respectively.
No interest expense has been charged on the net payable due to EndoSonics. The
following is an analysis of the payable to EndoSonics:
F-12
48
CARDIOVASCULAR DYNAMICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)
YEAR-ENDED
DECEMBER 31,
------------------------
1995 1996
--------- ---------
Beginning balance .................................................. $ 2,554 $ 2,537
Inventory purchases ................................................ 172 --
Corporate cost allocations ......................................... 340 156
Cash disbursements made by EndoSonicson behalf of CVD............... 312 --
Cash collections made by EndoSonics onbehalf of CVD................. (700) --
Cash payments to EndoSonics ........................................ -- (2,693)
Cash disbursements made by CVD on behalf of EndoSonics and other ...
(141) --
--------- ---------
Ending balance ..................................................... $ 2,537 $ --
========= =========
Average balance during period ...................................... $ 2,551 $ 1,974
========= =========
In connection with the initial public offering, CVD and EndoSonics entered into
a Tax Allocation Agreement that provides, among other things, for (i) the
allocation of tax liabilities and adjustments thereto as between the business of
the Company and other businesses conducted by EndoSonics and its affiliates
related to periods in which the Company is includable in consolidated federal
income tax returns filed by EndoSonics, (ii) the allocation of responsibility
for filing tax returns and (iii) the conduct of and responsibility for taxes
owed in connection with tax audits and various related matters.
EndoSonics and CVD had entered into a Stockholder Agreement providing that all
transactions between the Company and EndoSonics or any affiliate of EndoSonics
must be approved by a special committee of CVD's Board of Directors comprised of
two directors who are not officers, directors, employees or affiliates of
EndoSonics. The provisions of this agreement became effective upon the
consummation of the initial public offering and terminated in the fourth quarter
of 1997 when EndoSonics beneficially owned less than 25% of CVD's Common Stock.
See also Notes 5 and 11.
5. AGREEMENTS WITH FUKUDA AND CATHEX
The Company had a distribution agreement with Fukuda which provided them with
exclusive distribution rights relative to certain of the Company's products in
Japan for periods extending through May 1999, which could be extended at the
option of the parties. Distribution fee revenues received from Fukuda were
deferred and were being recognized as revenue over the initial periods covered
by the respective agreement.
In July 1995 and May 1996, the distribution agreement with Fukuda was amended.
In exchange for the exclusive distribution rights to additional CVD products,
the Company received $750 which converted into the right to receive 62,500
shares of Common Stock upon the consummation of the initial public offering. In
November, 1996, Fukuda exercised the conversion feature of said obligation. In
May 1997, the Company terminated the existing distribution agreement and does
not expect that any material obligations will arise as a result of such
termination.
The Company entered into a distribution agreement, dated May 1, 1997, with
Cathex, Ltd. (The "Cathex Agreement"), whereby Cathex serves as CVD's exclusive
distributor for certain of the Company's products in Japan. In exchange for this
exclusive distributorship, Cathex shareholders agreed to purchase $200,000 in
CVD
F-13
49
CARDIOVASCULAR DYNAMICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)
common stock or approximately 25,000 shares, in addition to payments owing upon
the purchase of the products. Cathex also agreed to undertake all necessary
clinical trails to obtain approval from Japanese regulator authorities for the
sale of the products in Japan. Cathex's purchases under the Cathex Agreement are
subject to certain minimum requirements. The initial term of the Cathex
Agreement expires on January 1, 2001, subject to a five-year extension. The
Cathex Agreement may also be terminated in the event of breach upon 90 days
notice by the non-breaching party, subject to cure within the notice period.
6. LICENSE AGREEMENTS
In January 1995 the Company entered into a license agreement with Advanced
CardioVascular Systems, Inc. ("ACS") under which the Company acquired the
exclusive worldwide rights to ACS' SmartNeedle technology. The Company assumed
responsibility for manufacturing the product in 1996, subject to the payment of
royalties. ACS was granted an option, which was exercised in February 1996, to
obtain exclusive worldwide rights to certain CVD perfusion technology. In
exchange for the perfusion technology, ACS was obligated to make milestone and
minimum royalty payments to CVD, and also has certain obligations to develop and
market the perfusion technology. An initial milestone of $150 was earned in the
year ended December 31, 1996. In February 1997, ACS elected to terminate the
perfusion technology agreement.
The Company entered into a license agreement with EndoSonics pursuant to which
CVD granted EndoSonics the non-exclusive, royalty-free right to certain
technology for use in the development and sale of certain products. In exchange,
CVD received the non-exclusive, royalty-free right to utilize certain of
EndoSonics' product regulatory filings to obtain regulatory approval of CVD
products.
7. MARKETABLE SECURITIES AVAILABLE-FOR-SALE
The Company's investments in debt securities are diversified among high credit
quality securities in accordance with the Company's investment policy. The
Company's investment portfolio is managed by a major financial institution. The
following is a summary of investments in debt securities classified as current
assets and available-for-sale at December 31, 1996 and 1997.
DECEMBER 31, 1996 DECEMBER 31, 1997
----------------------------------- ----------------------------------
Gross Gross
Unrealized Unrealized
Holding Holding
(Losses) Fair (Losses) Fair
Costs Gains Value Cost Gains Value
---------- ---------- ---------- ---------- ---------- ----------
U.S. Treasury and other agencies debt securities .. $ 10,000 $ (19) $ 9,981 $ 4,976 $ 30 $ 5,006
Corporate debt securities ......................... 15,563 189 15,752 19,621 146 19,767
---------- ---------- ---------- ---------- ---------- ----------
$ 25,563 $ 170 $ 25,733 $ 24,597 $ 176 $ 24,773
========== ========== ========== ========== ========== ==========
All short-term investments at December 31, 1996 and December 31, 1997 were due
within one year.
8. INVENTORIES
Inventories are stated at the lower of cost, determined on an average cost
basis, or market value. Inventories consisted of the following:
F-14
50
CARDIOVASCULAR DYNAMICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)
DECEMBER 31,
------------------
1996 1997
-------- --------
Raw materials $ 1,015 $ 1,285
Work in process 510 165
Finished goods 1,374 1,755
-------- --------
$ 2,899 $ 3,205
======== ========
9. ACCOUNTS PAYABLE AND ACCRUED EXPENSES
Accounts payable and accrued expenses consisted of the following:
DECEMBER 31,
------------------
1996 1997
-------- --------
Accounts payable ....................... $ 750 $ 1,374
Accrued payroll and related expenses ... 1,040 1,317
Accrued clinical studies................ 290 548
Other accrued expenses ................. 302 249
-------- --------
$ 2,382 $ 3,488
======== ========
10. COMMITMENTS
Operating Leases
The Company leases its administrative, research and manufacturing facilities and
certain equipment under long-term, noncancelable lease agreements that have been
accounted for as operating leases. Certain of these leases include scheduled
rent increases and renewal options as prescribed by the agreements.
Future minimum payments by year under long-term, noncancelable operating leases
were as follows as of December 31:
1998.................. $ 429
1999.................. 213
2000................... 80
2001................... 8
-----
$ 730
=====
Rental expense charged to operations for all operating leases during the years
ended December 31, 1995, 1996 and 1997, was approximately $171, $365 and $574,
respectively.
11. SHAREHOLDERS EQUITY
Preferred Stock
In February 1995, every two shares of the Company's outstanding Common Stock was
exchanged for one share of Series A Preferred Stock with a liquidation
preference of $6.58 per share. In March 1996, the Company issued 400,000 shares
of Series B Preferred Stock to EndoSonics at $20.00 per share for aggregate
proceeds of $8,000.
F-15
51
CARDIOVASCULAR DYNAMICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)
The preferred stockholders converted their shares to common shares upon the
consummation of the Company's initial public offering.
Stock Option Plan
In May 1996, the Company, adopted the 1996 Stock Option/Stock Issuance Plan (the
"1996 Plan") which is the successor to the Company's 1995 Stock Option Plan.
Under the terms of the 1996 Plan, eligible key employees, directors, and
consultants can receive options to purchase shares of the Company's Common Stock
at a price not less than 100% for incentive stock options and 85% for
nonqualified stock options of the fair value on the date of grant, a determined
by the Board of Directors. The Company has authorized 1,990,000 shares of Common
Stock for issuance under the 1996 Plan. At December 31, 1997, the Company had
48,000 shares of Common Stock available for grant under the 1996 Plan. The
options granted under the 1996 Plan are exercisable over a maximum term of ten
years from the date of grant and generally vest over a four year period. Shares
underlying the exercise of unvested options are subject to various restrictions
as to resale and right of repurchase by the Company which lapses over the
vesting period.
OPTION PRICE NUMBER
PER SHARE OF SHARES
------------ ---------
Balance at December 31, 1994 ......... $ 1.00 462,000
Granted .............................. $ 1.00 to $ 1.50 494,000
Exercised ............................ -- --
Forfeited ............................ -- --
Cancelled ............................ -- --
------------------- ---------
Balance at December 31, 1995 ......... $ 1.00 to $ 1.50 956,000
Granted .............................. $ 2.50 to $ 13.25 346,000
Exercised ............................ $ 1.00 to $ 1.50 (138,600)
Forfeited ............................ $ 1.00 to $ 13.25 (18,875)
Cancelled ............................ -- --
------------------- ---------
Balance at December 31, 1996 ......... $ 1.00 to $ 13.25 1,144,525
Granted .............................. $ 5.00 to $ 9.50 985,000
Exercised ............................ $ 1.00 to $ 2.50 (208,259)
Forfeited ............................ $ 1.00 to $ 13.25 (196,479)
Cancelled ............................ $ 6.87 (130,000)
------------------- ---------
Balance at December 31, 1997 ......... $ 1.00 to $ 13.25 1,594,787
=================== =========
On April 21, 1997, the Board of Directors approved repricing of the options
granted on August 5, 1996 at $13.25 per share and on November 4, 1996 at $12.50
per share. As a result of the repricing, the exercise price became $6.88 and the
vesting period on the aforementioned options started anew.
The following table summarizes information regarding stock options outstanding
at December 31, 1997:
WEIGHTED-
AVERAGE WEIGHTED-
OPTIONS REMAINING WEIGHTED- OPTIONS AVERAGE
RANGE OF OUTSTANDING CONTRACTUAL AVERAGE EXERCISABLE EXERCISE
EXERCISE PRICES AT 12/31/97 LIFE EXERCISE PRICE AT 12/31/97 PRICE
- --------------- ----------- ----------- -------------- ----------- ---------
$ 1.00-$ 1.50 505,287 7.5 $ 1.25 242,912 $1.22
2.50- 13.25 1,089,500 9.4 7.23 25,292 6.96
--------- -------
1.00- 13.25 1,594,787 8.8 5.33 268,204 1.76
========= =======
As of December 31, 1996 and 1997, 253,525 and 268,204 options were exercisable,
respectively.
F-16
52
CARDIOVASCULAR DYNAMICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)
The weighted-average grant-date fair value of options granted during 1995, 1996
and 1997, for options where the exercise price on the date of grant was equal to
the stock price on that date, was $0.40, $5.12 and $4.50. The weighted-average
grant-date fair value of options granted during 1995, 1996 and 1997, for options
where the exercise price on the date of grant was less than the stock price on
that date, was $1.44, $3.16 and $0.
During 1996, the Company recorded deferred compensation of approximately $150
for financial reporting purposes to reflect the difference between the exercise
price of certain options and the deemed fair value, for financial statement
presentation purposes, of the Company's shares of Common Stock. An additional
$437 of deferred compensation was recorded to recognize compensation for
non-employee option grants during the year ended December 31, 1997. Deferred
compensation is being amortized over the vesting period of the related options.
$119 and $179 of deferred compensation was amortized in the year ended December
31, 1996 and 1997, respectively.
Stock Purchase Plan
Under the terms of the Company's 1996 Employee Stock Purchase Plan (the
"Purchase Plan"), eligible employees can purchase Common Stock through payroll
deductions at a price equal to the lower of 85% of the fair market value of the
Company's Common Stock at the beginning or end of the applicable offering
period. A total of 200,000 shares of Common Stock are reserved for issuance
under the Purchase Plan. During 1997, a total of approximately 33,000 shares of
common stock was purchased at an average price of $8.18 per share.
12. INCOME TAXES
Significant components of the Company's deferred tax assets are as follows at
December 31:
1996 1997
---------------------- ----------------------
Federal State Federal State
---------- ---------- ---------- ----------
Net operating loss carryforward ....... $ 1,792 $ 44 $ 3,899 $ 60
Accrued expenses ...................... 456 78 346 59
Research and development credits ...... 256 144 521 291
Bad debt reserve ...................... 132 23 175 30
Depreciation .......................... 52 9 (48) (8)
Inventory write-downs ................. 51 9 385 66
Capitalized research and development .. -- 276 -- 642
Deferred revenue ...................... 28 5 -- --
Other ................................. 47 57 163 28
---------- ---------- ---------- ----------
Gross deferred tax assets ............. 2,814 645 5,441 1,168
Valuation allowance ................... (2,814) (645) (5,441) (1,168)
Total deferred tax assets ............. -- -- -- --
---------- ---------- ---------- ----------
Net deferred tax assets ............... $ -- $ -- $ -- $ --
========== ========== ========== ==========
The valuation allowance increased by $3,150 and $1,569 in 1997 and 1996,
respectively.
The Company's effective tax rate differs from the statutory rate of 35% due to
federal and state losses which were recorded without tax benefit.
At December 31, 1997, the Company has net operating loss carryforwards for
federal and state income tax purposes of approximately $11,000,000 and
$1,000,000, respectively, which expire in the years 1998 through 2010. In
addition, the Company has research and development tax credits for federal and
state income tax purposes of approximately $520,000 and $320,000, respectively,
which expire in the years 2008 through 2011.
Because of the "change of ownership" provision of the Tax Reform Act of 1986,
utilization of the Company's net operating loss and research credit
carryforwards may be subject to an annual limitation against taxable income in
future periods. As a result of the annual limitation, a portion of these
carryforwards may expire before ultimately becoming available to reduce future
income tax liabilities.
F-17
53
CARDIOVASCULAR DYNAMICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)
13. EMPLOYEE BENEFIT PLAN
The Company provides a 401(k) Plan for all employees 21 years of age or
older with over 3 months of service. Under the 401(k) Plan, eligible employees
voluntarily contribute to the Plan up to 15% of their salary through payroll
deductions. Employer contributions may be made by the Company at its discretion
based upon matching employee contributions, within limits, and profit sharing
provided for in the Plan. No employer contributions were made in 1996 and 1997.
14. FOURTH QUARTER ADJUSTMENTS
Adjustments were made in the fourth quarter of 1997 to increase the
reserve for excess and obsolete inventories by $955, increase the allowance
for doubtful accounts by $270 and to accrue expenses of $780.
F-18
54
CARDIOVASCULAR DYNAMICS, INC.
SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS
YEARS ENDED DECEMBER 31, 1997, 1996, AND 1995
(IN THOUSANDS)
COLUMN A COLUMN B COLUMN C COLUMN D COLUMN E
-------- -------- -------- -------- --------
ADDITIONS
-----------------------
BALANCE AT CHARGES TO CHARGED BALANCE AT
BEGINNING COSTS AND TO OTHER END OF
DESCRIPTION OF PERIOD EXPENSES ACCOUNTS DEDUCTIONS PERIOD
----------- ---------- ---------- ---------- ---------- ----------
Year ended December 31, 1997
Allowance for doubtful accounts ... $ 377 $ 318 $ -- $ (195) $ 500
Accrued warranty expenses ......... $ 29 $ -- $ -- $ (29) $ --
Reserve for excess and obsolete
inventories...................... $ 145 $ 955 $ -- $ -- $ 1,100
Year ended December 31, 1996
Allowance for doubtful accounts ... $ 180 $ 221 $ -- $ (24) $ 377
Accrued warranty expenses ......... $ 113 $ -- $ -- $ (84) $ 29
Reserve for excess and obsolete
inventories...................... $ 209 $ -- $ -- $ (64) $ 145
Year ended December 31, 1995
Allowance for doubtful accounts ... $ 85 $ 95 $ -- $ -- $ 180
Accrued warranty expenses ......... 20 $ 93 $ -- $ -- $ 113
Reserve for excess and obsolete
inventories...................... $ -- $ 209 $ -- $ -- $ 209
II-1
55
EXHIBIT INDEX
DESCRIPTION SEQUENTIALLY
EXHIBIT NUMBER
- ------- PAGE
------------
2.1(3) Agreement and Plan of Reorganization dated as of June 9, 1993 among
EndoSonics Corporation ("EndoSonics"), EndoSonics Acquisition
Corporation and CardioVascular Dynamics, Inc. ("CVD")........................
2.2(3) First Amendment dated as of June 30, 1993 to the Agreement and Plan of
Reorganization among EndoSonics Acquisition Corporation and CVD..............
2.3(5) Agreement and Plan of Reorganization by and among CardioVascular
Dynamics, Inc., IDI Acquisition Corporation and Intraluminal Devices,
Inc. ("IDI") dated as of October 2, 1996.....................................
3.1(3) Certificate of Incorporation.................................................
3.2(3) Amended Bylaws...............................................................
4.1(1) Specimen Certificate of Common Stock.........................................
10.1(3) Form of Indemnification Agreement entered into between the
Registrant and its directors and officers ...................................
10.2(3)** The Registrant's 1996 Stock Option Plan and forms of agreements
thereunder ..................................................................
10.3(3)** The Registrant's Employee Stock Purchases Plan and forms of agreement
thereunder...................................................................
10.4(3) Series A Supplemental Stock Purchase Agreement dated June 5, 1992, and
by between the EndoSonics and CVD ...........................................
10.5(3) Stock Purchase Option agreement dated June 5, 1992, by and between
EndoSonics and CVD ..........................................................
10.6(3)* Japanese Distribution Agreement dated May 28, 1993, as amended on
October 27, 1994 and July 17, 1995, (the "Japanese Distribution
Agreements") by and between CVD and Fukuda Denshi Co., Ltd. ("Fukuda") ......
10.7(3)* Stock Purchase and Technology License Agreement dated September 10,
1994, as amended on September 29, 1995, by and among EndoSonics, CVD
and SCIMED Life Systems, Inc. ("SCIMED").....................................
10.8(3) Waiver and Grant of Warrant Dated June 30, 1995 by and between SCIMED,
CVD and EndoSonics ..........................................................
10.9(3)* License Agreement dated January 15, 1995 by and between CVD and
Advanced CardioVascular Systems, Inc. ("ACS")................................
10.10(3) License Agreement dated March 4, 1996 by and between CVD and ACS ............
10.11(3) Series B Stock Purchases Agreement dated March 29, 1996 and between
CVD and EndoSonics ..........................................................
10.12(3) License Agreement dated December 22, 1995 by and between CVD and
EndoSonics ..................................................................
10.13(1) Form of Stockholder Agreement with EndoSonics ...............................
10.14(1) Form of Tax Allocation Agreement with EndoSonics ............................
10.15(3) Industrial Lease dated February 23, 1995 by and between the Irvine
company and CVD .............................................................
10.16(1) Waiver and Grant of Warrant dated May 2, 1996 by and between SCIMED,
CVD and EndoSonics ..........................................................
10.17(2) Amendment to Japanese Distribution Agreements dated May 13, 1996 by
and between CVD and Fukuda ..................................................
10.18(4)* Supply Agreement dated July 15, 1996 by and between CVD and Medtronic,
Inc. ........................................................................
10.19(4)* OEM Agreement dated July 15, 1996 by and between CVD and Medtronic,
Inc. ........................................................................
10.20(6) License Agreement dated May 16, 1997 by and between CVD and
EndoSonics...................................................................
10.21(6) Registration Rights Agreement dated May 14, 1997 by and between CVD and
EndoSonics...................................................................
10.22(7)** 1997 Supplmental Stock Option Plan...........................................
II-2
56
EXHIBIT INDEX
DESCRIPTION SEQUENTIALLY
NUMBER
EXHIBIT PAGE
- ------- ------------
23.1 Consent of Ernst & Young LLP, Independent Auditors...........................
24.1 Power of Attorney (Reference is made to signature pages of this Annual Report
on Form (10-K) ..............................................................
27.1 Financial Data Schedule......................................................
* Confidential treatment granted
** Indicates compensatory plan or arrangement.
(1) Previously filed as an exhibit to Amendment No. 2 to the Company's
Registration Statement on Form S-1 filed with the Securities and Exchange
Commission on June 10, 1996.
(2) Previously filed as an exhibit to Amendment No. 1 to the Company's
Registration Statement on Form S-1 filed with the Securities and Exchange
Commission on May 17, 1996.
(3) Previously filed as an exhibit to the Company's Registration Statement on
Form S-1 filed with the Securities and Exchange Commission on May 3, 1996.
(4) Previously filed as an exhibit to the Company's report on Form 10-Q filed
with the Securities and Exchange Commission on August 14, 1996.
(5) Previously filed as an exhibit to the Company's Registration Statement on
Form S-1 filed with the Securities and Exchange commission on November 12, 1996.
(6) Previously filed as an exhibit to the Company's Registration Statement on
Form S-1 filed with the Securities and Exchange Commission on June l9, 1997.
(7) Previously filed as an exhibit to the Company's Registration Statement on
Form S-8 filed with the Securities and Exchange Commission on December 12, 1997.
II-3